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2.   Thesis abstract 
Alzheimer’s disease (AD) is the most prevalent form of dementia that has vast emotional and 
economic implications in our society. There is no cure for this neurodegenerative disorder as 
the pathological changes occur years before the manifestation of the clinical symptoms. 
Thus, there is a great need for the development of effective and non-invasive biomarkers 
allowing the identification of patients at risk. During my Ph.D., I used next generation 
sequencing to study the small noncoding RNAome in the exosomes derived from 
cerebrospinal fluid (CSF), the majority of which are microRNAs (miRNAs) and piwi-
interacting RNAs (piRNAs). Statistical and machine learning methods were able to identify 
putative miRNAs and piRNAs signature that can classify AD and controls with an AUC of 
0.83. The piRNAs signature was suitable to predict conversion of patients suffering from mild 
cognitive impairment (MCI) to AD with an AUC of 0.86. The putative signature performed 
even better in the brain region with an AUC of 0.89 suggesting that we can use the 
smallRNAs signatures to perform a good diagnosis and prognosis between AD and controls. 
 
To better understand the mechanism that disrupts the human homeostasis leading to 
several neurodegenerative disorders, in a pilot study, I looked into the dynamic changes in 
higher order chromatin structure that control gene expression programs in synaptic plasticity, 
memory function, and neurodegenerative disorders by the use of Chromosome 
Conformation Capture (3C) based technique (3C-seq). One finding was related to the 
hallmark of AD (Aβ plaques). There was a preference of looping interactions involving 
BACE1 gene (initiates the Aβ generation that leads to the formation of Aβ plaques) in the 
neuronal population compared to the non-neuronal population. The results, however, for this 
pilot study should be interpreted cautiously due to small sample size and availability of the 
low resolution data.  
 
My study thus aims to provide further evidence that circulating small noncoding RNAs could 
be a suitable biomarker to detect the Alzheimer’s disease.  As these small noncoding RNAs 
are extremely stable both longitudinally and during the experimental procedures, they make 
excellent candidates for biomarkers for the prediction of the disease onset. The study also 
focuses on standardization and replication of the results by providing an open source access 
to the statistical and machine learning pipelines that were developed during the course of 
this study. This work also provides new insights to the genome stability, functions and the 
underlying mechanisms that are responsible for the correct gene expression in the genome 
and disruption of which causes these neurodegenerative disorders. 
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5.   List of Abbreviations 
3C Chromosome Conformation Capture 
3D Three-dimensional 
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APP Amyloid-Beta Precursor Protein 
AUC Area Under the Curve 
AUROC Area Under the Receiver Operating Characteristic Curves 
Aβ Amyloid-Beta 
BACE1 Beta-Secretase 1 
BAM Binary Alignment Map 
CA1 Cornu Ammonis1 
CSF Cerebrospinal Fluid 
CSV Comma Separated Values 
CT Computed Tomography 
DNA Deoxyribonucleic Acid 
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FTD Frontotemporal Dementia 
ILV Intraluminal Vesicle 
JSON JavaScript Object Notation 
MANCOVA Multivariate Analysis of Covariance 
MCI Mild Cognitive Impairment 
miRNA MicroRNA 
MM9 Mus Musculus 9 (Build 37) 
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MVB Multivesicular Bodies 
ncRNA Non-coding RNA 
NGS Next Generation Sequencing 
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pimiRNA Piwi-interacting/Micro-RNA 
piRNA Piwi-Interacting-RNA 
pTAU Phosphorylated TAU 
QC Quality Check 
qPCR Quantitative Polymerase Chain Reaction 
RNA Ribonucleic Acid 
ROC Receiver Operating Characteristic Curves 
SAM Sequence Alignment Map 
sncRNA Small non-coding RNA 
TADs Topologically Associating Domain 
TSS Transcription Start Site 
TSV Tab Separated Values 
XML eXtensible Markup Language 
 Introduction  20 
6.   Introduction 
6.1 Introduction to neurodegenerative disorders 
6.1.1 Potential classification of neurodegenerative diseases 
Neurodegenerative disorders belong to the category of disorders and diseases that are 
mainly associated with the neurons. They are identified by the escalating loss of neuronal 
structure and/or functions mostly in the brain and spinal cord [1, 2]. At present there are 
various treatment strategies that had seen different levels of success, but there are no cures 
for these disorders. These neurodegenerative disorders can broadly be classified into two 
categories on the basis of their effects. They can either affect the movements of the muscles 
or can cause cognitive decline [3, 4]. A selected list of few neurodegenerative disorders are 
mentioned in Table 6-1. 
Table 6-1 A small description of selected list of neurodegenerative disorders 
Disorders Description 
Alzheimer’s disease (AD) 
• The most common causes of dementia and 
characterized by the accumulation of amyloid 
plaques and neurofibrillary tangles 
• Symptoms include memory and cognitive 
decline 
• Disease onset starts around age 40 
Schizophrenia (SCZ) [5] 
• Psychotic disorder resulting in 
neurodegeneration  
• Symptoms include hallucinations, delusions and 
disorganized behavior  
• Disease onset starts in the early 20s 
Bipolar disorders (BD) 
• Majorly identified by extreme mood swings 
• Symptoms range from low depressive episodes 
to high maniac episodes 
• Disease onset starts around age 25 
Prion disease (CJD) • Also known as Creutzfeldt-Jacob disease and 
mainly characterized by amyloid plaques and 
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spongiform 
• Symptoms include fast progressive dementia 
and changes in behavior 
• Usual disease onset is around age 60 
Amyotrophic Lateral Sclerosis (ALS) 
• Also known as Lou Gehrig's disease and mainly 
characterized by progressive degeneration of 
the muscles which results in paralysis 
• Symptoms include muscle weakness and 
paralysis 
• Disease onset starts in early teenage 
Parkinson's Disease (PD) 
• Chronic progressive disorder characterized by 
bradykinesia, tremors, impairment of postural 
balance and rigidity 
•  Apart from above mentioned characteristics, 
symptoms also include stress, anxiety, 
depression, memory loss and dementia    
• Usual disease onset is around age 60 
Spinocerebellar ataxia (SCA) 
• An autosomal dominant neurodegenerative 
disorder and mainly caused by ATNX1 gene 
mutation on chromosome 6 
• Symptoms include spasticity, dysarthria, gait 
difficulty and loss of coordination 
Dystonia 
• Characterized by agonizing and extended 
muscle contractions causing irregular postures 
and movements 
• Major symptoms include muscle cramps and 
spasms 
• Disease onset starts as early as the age of 12 
Multiple System Atrophy (MSA) 
• Also known as "Shy Drager", "Striatonigral 
degeneration" or "Olivopontocerebellar Atrophy"  
• Symptoms mainly include Parkinsonism, 
autonomic failure, and cerebellar findings 
• Disease onset starts around age 40 
Huntington's Disease (HD) • An autosomal dominant progressive 
neurodegenerative disorder caused by a defect 
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in HTT (Huntington) gene on chromosome 4 
• Symptoms include impaired gait, involuntary 
movements or rigidity in the muscles and 
cognitive decline 
• Disease onset starts around age 40 
Rett Syndrome 
• A neurodevelopmental disorder primarily 
affecting girl child 
• Symptoms include diminished motor skills, 
chorea, microcephaly 
• Disease onset starts around age of 6 months 
Progressive Supranuclear Palsy (PSP) 
• Also known as Steele-Richardson-Olszewski 
syndrome affecting stance and cognitive abilities 
• Symptoms include progressive hindrance of 
speech and swallowing, limited mobility and 
imbalance 
• Disease onset starts around age 55 
Tourette Syndrome 
• Mainly characterized by involuntary tics, 
twitching and uncontrollable vocal outbursts  
• Symptoms include motor and vocal tics and do 
not stop during sleep 
• The disease onset typically starts around age 7 
years 
6.1.2 The partnership of aging and neurodegeneration 
The advancement in modern medicine has increased the average lifespan with an unwanted 
side effect in the form of neurodegenerative diseases. These diseases are a major concern 
all over the world as they are one of the leading causes of disability in the elderly and 
ultimately lead to death. With the aging, the human brain starts to aggregate and accumulate 
abnormal and misfolded proteins causing lesions to the affected brain regions. With the 
progressive loss of neurons over the course of many years, it is very hard to estimate the 
real reason for the cell deterioration and ultimately the death of the neurons. Some important 
neuronal cell death mechanisms include Autophagy, apoptosis, excitotoxicity, and necrosis 
[6]. It is still a big challenge to understand how aging only affects the growth of the neurons 
and can be distinguished solely from the neurodegeneration.  
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6.1.3 Effects of neurodegeneration: The big picture 
The worldwide threat to human health from these disorders is increasing every day 
disturbing the lives of the patients, families and the community in general. Almost all 
neurodegenerative disorders are incurable to date and a huge amount of resources are 
being allocated to find the cure for these diseases. Developing a deep understating of the 
pathology and onset of disease progression is very important. For example, use of animal 
model systems to understand the working of certain disorders can play a major role in 
identifying key mechanisms of these neurodegenerative disorders. The final aim is to 
develop biomarkers that can identify, classify and ultimately predict the onset of the disease 
progression. 
6.2 Overview of dementia 
6.2.1 Mild Cognitive Impairment (MCI) 
6.2.1.1 MCI: normal aging or dementia? 
The decline of cognitive abilities due to aging remains an increasing problem in today’s 
world. Further, considering everyone with a diminished cognition to be diagnosed as an early 
form of Alzheimer’s disease (Alzheimer’s disease) is misleading. With the improvement in 
the disease diagnosis, it is easier to classify most of these cases as mild cognitive 
impairment (MCI) [7]. In MCI, a person is suffering from diminished cognition typically related 
to judgement, thinking, vocal skills and memory is worse than the average age-matched 
individual. The individuals with MCI may lead a relatively normal life as these symptoms are 
not enough to be classified as dementia [8]. However, there is a decent chance that an 
individual suffering from MCI may go on to have dementia. Proper care at this stage in term 
of lifestyle may help individuals to keep the symptoms same or even get better [9]. 
6.2.1.2 Symptoms of MCI 
An individual suffering from MCI display some or all of the below-mentioned symptoms [10, 
11]: 
• Memory complains which relates the diminishing of memory. This is mostly related to 
forgetting events like appointments 
• Diminishing of communication skills 
• Showing poor judgement and becoming more spontaneous 
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• Trouble keeping up a line of thoughts and taking extra time during the decision 
making 
All of the above mentioned symptoms are worse compared to normal aging but not enough 
to be classified as dementia [12]. 
6.2.1.3 Potential causes of MCI 
There are multiple causes to MCI some of which are treatable. It becomes more challenging 
to identify the real cause of MCI as the symptoms may improve over time or stay as it is or 
may deteriorate to dementia. As most of the causes of MCI are not understood, some of 
them have shown an improved understanding. Most of these causes are similar to dementia 
[13]. These include accumulation of amyloid plaques, Lewy bodies and misfolded protein 
tangles, neuronal injuries (motor or sensory signs), decreased levels of the CSF and 
shrinkage of the brain region mainly hippocampus, which is associated with episodic 
memory [14]. Figure 6.2-1 [15] left shows the normal hippocampal region while the shrunken 
hippocampus related to MCI is shown in the right. 
 
Figure 6.2-1 Brain shrinkage. The MRIs shows reduction in hippocampal region responsible 
for memory. Brain with normal cognitive function (Left) and suffering from Mild Cognitive 
Impairment (MCI) on the right. Inset shows the an overview of the right hippocampal region.  
6.2.1.4 Clinical criteria for the diagnosis of MCI and treatment 
Individuals suffering from MCI are difficult to diagnose as there are no specific protocols 
defined. However, there are certain clinical guidelines that are defined and followed by 
clinicians all over the world to perform the MCI diagnosis [16]. It is also important that these 
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guidelines also distinguish individuals suffering from MCI to dementia and Alzheimer’s 
disease [17]. These guidelines include: 
• A decline in cognitive performance over time 
• Memory and other reasoning abilities are impaired 
• A lookout for brain shrinkage, tumors and strokes using brain imaging techniques like 
MRI or CT scan 
• All the diagnosis of dementia and Alzheimer’s disease should be negative 
• Activities of daily living (ADL) should be intact 
 
There are currently no treatments available for MCI. However, few medications that are used 
for dementia and Alzheimer’s disease are used for MCI patients, but they do not always 
work. There is major research going on the development of biomarkers for MCI and a better 
understanding of MCI will definitely lead to a better understanding of dementia and 
Alzheimer’s disease [12]. 
6.2.2 Dementia 
6.2.2.1 Dementia – Information and Statistics 
Dementia can be broadly stated in terms of mental decline of an individual that negatively 
affects their life on a day to day basis [18]. In order to classify an individual to have 
dementia, there should be significant impairment in their mental abilities, communication 
skills, and long & short term memory.  Dementia affects about 50 million people worldwide 
with an annual increase of 7.7 million cases every year and the number of people with 
dementia are expected to triple by the year 2050. The economic burden caused by dementia 
is expected to be around 818 billion USD per annum and is the 7th leading cause of death 
worldwide [19, 20]. 
6.2.2.2 Symptoms of Dementia 
Dementia cannot be classified as a disease in clinical terms, but can be referred to as an 
umbrella term for a set of symptoms that collectively describes the decline in the cognitive 
abilities of a person that impairs their daily activities [21, 22]. Some common symptoms 
include: 
• Memory loss, disturbing daily life 
• Consistently displaying poor judgement 
• Irregular moods and behavior 
• Communication and language disturbances 
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• Overall increase in disorientation and confusion 
• Inability to show proper reasoning  and thinking 
The above mentioned symptoms are generally known as primary symptoms and often 
followed up with more in-depth and through check-ups in the clinics [23].   
6.2.2.3 Dementia - Types and Causes 
Dementia is majorly caused by loss of neurons in the brain. This affects the thinking, 
judgement and emotional balance of the individual [24]. Dementia is mainly classified into 
five subtypes [25]. They are: 
• Alzheimer’s Disease (Alzheimer’s disease) which is the most common form of dementia 
showing memory, language and spatial decline  
• Vascular Dementia (VaD) also known as multi-infarct dementia experiencing an abrupt 
onset and associated with vascular risk factors like stroke 
• Lewy Body Dementia (DLB) with individuals experiencing hallucinations 
• Fronto-Temporal Dementia (FTD) exhibiting behavior and personality changes 
• Other Dementias associated with other neurodegenerative diseases like Parkinson’s 
disease (PD), Huntington’s disease (HD), Creutzfeldt-Jakob disease, Progressive 
supranuclear palsy, Prion diseases etc. 
 
Figure 6.2-2 shows the MRI of the brain from different individuals who observed the changes 
in the white matter of three different individuals, one suffering from Vascular Dementia, one 
suffering from Lewy Body Dementia and an age-matched control. The changes progressed 
to worse from the control to Vascular Dementia [26]. 
 
 
 Introduction  27 
Figure 6.2-2 Axial proton density MRI showing white matter lesions and rating. A. Normal 
aged matched individual used as a control. B. Individual suffering from Vascular Dementia. 
C. An individual suffering from Lewy Body Dementia (Adapted from Barber et.al. [26]) 
 
Figure 6.2-3 displays the most common forms of dementia. Alzheimer’s disease accounts for 
almost two-thirds of all forms of dementia, contributing approximately 11.6% of all recorded 
deaths worldwide [25, 27].  
 
 
Figure 6.2-3 Types of Dementia 
6.2.3 Alzheimer’s Disease (AD) 
6.2.3.1 An overview of Alzheimer’s disease 
As mentioned in the previous section 6.2.2.3 above, Alzheimer’s disease is the most 
common cause of dementia, accounting for almost two-thirds of dementia cases. It is a 
progressive neurodegenerative disorder where the symptoms get worse and worse over 
time. Figure 6.2-4 shows the progression of Alzheimer’s disease patient over time and 
distinguishes between normal aging and Alzheimer’s disease. Approximately 45 million 
individuals are suffering from Alzheimer’s disease worldwide with one new case of dementia 
is occurring every 3.2 seconds and expected to be around 131 million by mid of the 21st 





Alzheimer’s Disease (AD)  
Vascular Dementia (VaD)
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Figure 6.2-4 Estimated yearly cases of Alzheimer's disease. Source World Alzheimer Report 
(2016) 
6.2.3.2 Disease pathology of Alzheimer’s disease 
There are two established pathological hallmarks of Alzheimer’s disease shown in Figure 
6.2-5 [29]. They are: 
• β-amyloid (Aβ) plaques also known as senile plaques(SPs) are the extracellular 
deposits of beta-amyloid peptides. These Aβ deposits are toxic to neurons as they 
cause loss of long term potentiation (LTP) and leads to neuronal death 
• Neurofibrillary Tangles (NFTs) also known as neuritic plaques or neuropil threads are 
characterized as intracellular accumulation of the insoluble hyperphosphorylated paired 
helical filaments of tau proteins that are associated microtubules 
 
Aβ deposits are very specific to Alzheimer’s disease and characterized to be the primary 
cause of Alzheimer’s disease, but their deposition amount does not correlate well with 
increasing dementia. Accumulation of tau proteins which second pathological hallmark of 
Alzheimer’s disease is also observed in other neurodegenerative diseases like FTD and 
prion disease. Hence, they were considered secondary to Aβ deposits. However, their 
accumulation amount correlated well with increasing dementia and became the foundation of 
Braak and Braak staging system of Alzheimer’s disease [30].  
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Figure 6.2-5 Amyloid plaques and tau neurofibrillary tangles in a human Alzheimer’s disease 
brain.  
The histopathology shows the Aβ plaques and neurofibrillary tangles in cortical tissue of an 
Alzheimer’s disease suffering individual. A.  Brown stains (spherical lesions) show amyloid-β 
plaques. B. Neurofibrillary tangles are shown by black arrows and neuropil threads shown by 
the white arrows. (Adapted from Nicoll et.al. [29]) 
6.2.3.3 Stages and Symptoms of Alzheimer’s disease 
As Alzheimer’s disease is the most common form of dementia, its symptoms are also the 
same to start with. They include loss of memory and disorientation, having difficulty with 
communication and rational thinking, displaying poor judgement and inability to learn new 
skills [31]. Alzheimer’s disease is a progressive neurodegenerative disorder and the disease 
progression occurring in various stages (Figure 6.2-6).  
A B 
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Figure 6.2-6 A model of progression of Alzheimer’s disease.  A hypothetical model showing 
the progression of a normal individual from healthy to Alzheimer’s disease with the decline in 
cognition. The solid line representing aging shows a normal decline in cognitive functions 
compared to a demented individual (represented by dotted lines) 
 
The main stages that characterize Alzheimer’s disease are [32]: 
• Preclinical Alzheimer’s disease: There is a distinct lack of any clinical symptoms of 
Alzheimer’s disease at this stage [33]. Although the changes in the pathology have 
already begun by the accumulation of insoluble proteins. This typically goes on for years 
without any visible symptoms. The advent of new diagnostic techniques is now helping 
in diagnosing Alzheimer’s disease at this stage. The new Cerebrospinal fluid (CSF) 
biomarkers and advanced imaging techniques are showing some positive results 
 
• MCI due to Alzheimer’s disease: Individuals suffering from an MCI start to show the 
sign of cognitive decline [12]. Although not all individuals go to develop Alzheimer’s 
disease, the ones that do show a consistent progression in the loss of memory and 
other cognitive tasks starts to get their daily life affected 
 
• Mild Alzheimer’s disease: This is one of the early stages where Alzheimer’s disease is 
clinically diagnosed as an individual shows worsen symptoms in terms of memory, 
thinking, judgement, organization skills and behavior. They are still able to act 
independently, but their daily life activities started to get affected [34, 35] 
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• Moderate Alzheimer’s disease: This is the stage where the individual started to show 
obvious and clear signs of dementia [36]. This stage can last for several years where an 
individual starts to forget important personal information and events, erratic sleeping 
patterns, increasing the risk of getting lost, changes in the personality and behavior [37] 
 
• Severe Alzheimer’s disease: The final stage of Alzheimer’s disease where the 
individual their independence to do daily activities and requires constant care. At this 
stage, they are unable to respond to their environment, losing awareness of their 
surroundings, increasing episodes of forgetting family members with difficulty in 
communicating with them and a steep decline in performing physical activities [38] 
 
The disease onset is progressive and happens gradually over the years. The average life 
span after the diagnosis of Alzheimer’s disease is between 10 to 20 years [39, 40].  
6.2.3.4 Diagnosis and treatment of Alzheimer’s disease 
Like all neurodegenerative diseases, there is no cure for Alzheimer’s disease. The treatment 
can prolong the symptoms and may slow down the decline of cognitive abilities but they 
cannot stop them. The diagnosis is also improving with time. Doctors and clinicians are now 
looking at the detailed medical and family history of the individual suffering from Alzheimer’s 
disease in order to get a bigger picture of the individual’s development of the Alzheimer’s 
disease symptoms [41]. This may also help them diagnose Alzheimer’s disease at an earlier 
stage and help them slow down the disease progression [42]. Various other diagnostic tools 
include various laboratory tests for metabolic disorders, physical tests to check muscle 
strengths, cognitive and behavioral tests to check for mental abilities [43, 44]. The new 
diagnostic tools involve the imaging techniques like MRI [45], PET [46, 47], CT scans [48, 
49]and the use of new Cerebrospinal fluid (CSF) biomarkers to look the levels of beta 
amyloid plaques and neurofibrillary tangles [50-54]. The role of small non-coding RNAs like 
miRNAs and piRNAs can also be used as potential diagnostic tools in the future [55-58].  
6.3 Exosomes 
6.3.1 Overview of Exosomes 
Extracellular vesicles (EVs)[59] are released by all cells and historically were called “debris” 
as their functions were unknown. There are many types of extracellular vesicles that include 
microvesicles, ectosomes and exosomes. Microvesicles are groups of small vesicles that are 
budded off from the surface of cells through a bidding mechanism. They may be released 
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containing surface receptors, which can attach to the surface of another cell or may be 
completely taken up by another cell. Ectosomes are multisized vesicles mostly larger than 
exosomes that are secreted directly from the plasma membrane into the extracellular space 
[60]. Exosomes are smaller vesicles compared to the microvesicles and are produced by 
multivesicular endosomes (Figure 6.3-1) [61] which carries different types of cellular 
materials [62]. They are also taken up by other cells. 
 
Figure 6.3-1 Exosome Electron micrograph. Exosomes secreted from Epstein–Barr virus-
transformed B cell and multivesicular bodies (MVB). The MVBs content is either degraded in 
lysosomes or more exosomes are released after their fusion with the cellular membrane. 
Adapted from Edgar et. al. [61] 
6.3.2 Biogenesis and functions of exosomes 
Exosomes are normally 30-150nm sized vesicles, which are indicated that are derived from 
the multi-vesicular bodies. Exosomes are generated via endocytic pathways when cell 
internalizes receptors and deliver them to lysosomes for degradation by proteolysis [63]. The 
process begins (Figure 6.3-2) [64] when the cell surface receptors containing small peptides 
ubiquitin which marks them for degradation are fused inward into an endosome that 
squeezes into the interior of the endosome through invagination that results in a small 
intraluminal vesicle (ILVs) which goes to build many more of these ILVs and resulting in the 
formation of multi-vesicular bodies (MBVs). These MBVs primarily known to deliver the ILVs 
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to the lysosomes  where these ILVs were degraded into sugars and amino acids to be used 
again by the cell. In the past couple of decades, another pathway is known where the MBVs 
instead of delivering the ILVs to the lysosomes for the degradation, actually travel to the cell 
surface where they fuse with the plasma membranes and the ILVs were expelled into the 
extracellular space which are now known as exosomes. The working mechanism of these 
pathways is still unclear [65]. These exosomes then can be targeted to other cells and 
tissues and the molecules that are contained within the exosomes are then be internalized 
by these targets to affect the signaling pathways or expression of the genes.  
 
Figure 6.3-2 Schematic of exosomes biogenesis. The surface receptors buds to smallRNAs 
and proteins in cytoplasm ILVs after budding with MBVs. From there they can either release 
exosomes or get degraded in lysosomes. Adapted from Schorey et. al. [64] 
Many biological functions have been identified for exosomes [63, 65]. They can act as 
proteins which are expelled out of the cells during some other cellular processes [66]. These 
also act as clearance mechanisms where unwanted proteins are secreted out of the cells. 
They have also been known to regulate immune response where their role in coagulation 
and inflammation are reported [67, 68]. They also function as messengers between cells, 
especially in neurons. They can also be selected where they are only captured and 
internalized by certain cell types [69]. 
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6.3.3 Role of exosomes in Alzheimer’s disease 
The two pathological hallmarks of Alzheimer’s disease are Aβ plaques and neurofibrillary 
tangles. The removal of unwanted materials from the cells through exosomes has been 
established and neurons use the exosomes to clear out the toxic beta amyloid (Aβ) proteins 
[70] (Figure 6.3-3).  These toxic beta amyloid (Aβ) proteins accumulate in the endosomes 
and their ILVs are then transported out as exosomes after the fusion of their respective 
MVBs to the cell membrane into the extracellular space [71].  
 
 
Figure 6.3-3 Aβ proteins clearance through exosomes. Amyloid-β precursor protein (APP) 
gets cleaved to form Amyloid-β (Aβ) proteins. They are then released into the extracellular 
space through exosomes. Adapted from Yuyama, K et.al. [71] 
Second hallmark of Alzheimer’s disease, the neurofibrillary tangles associated with 
hyperphosphorylated microtubule associated tau protein is also secreted through the use of 
exosomes [72-74]. In the clinics, increased levels of phosphorylated tau proteins were 
observed from the blood exosomes of Alzheimer’s disease patients in comparison to the 
age-matched controls [75].  
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6.3.4 Exosomes as potential biomarkers for Alzheimer’s disease 
Exosomes can be excellent candidate biomarkers for early stage Alzheimer’s disease. 
Exosomes extracted from the cerebrospinal fluid (CSF) contains neurons and non-neuronal 
markers like beta-amyloid (Aβ) proteins, tau proteins and pTAU proteins. By checking at the 
levels of these proteins from the CSF exosomes, it is possible to diagnose an individual with 
MCI or Alzheimer’s disease [76, 77]. Exosomes also contains small non-coding RNAs like 
miRNAs and piRNAs which may also be used as potential biomarkers for the classification of 
Alzheimer’s disease from their aged matched controls [78, 79]. 
6.4 Biomarkers  
6.4.1 Definition of a biomarker 
A biomarker or “biological marker” is anything that can be measured as an indicator of a 
biological process which can range from anything is going on in the body, whether it is a 
normal development of the body or response of an individual’s body to a particular medicine 
[80].  These can range from simple measurements like blood pressure or cholesterol levels 
to complex measurements like the levels of tau proteins. Biomarkers can be used to provide 
information about an individual’s risk of developing a particular disease, the prognosis of that 
disease and to predict response to a particular medication for that disease [81]. 
Individualized medicine critically relies on the development of biomarker [82, 83]. Especially 
for slowly processing brain diseases, it is important to: 
• Develop markers that are rather stable over time in a healthy population 
• Safe an easy to measure 
• Cost efficient 
• Inform about treatment efficacy 
6.4.2 Types of biomarkers 
Biomarkers fall into two major categories; Prognostic and Predictive [81, 84].  
• Prognostic biomarkers can provide us with information regarding the progression of a 
disease. They are unaffected to the treatment plan and strategies of a particular patient 
suffering from the disease. These biomarkers are useful in the prognosis of the patient 
as to how aggressive the treatment plan should be in order to approach the treatment of 
the disease 
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• Predictive biomarkers can provide the prediction about the therapeutic outcome for a 
patient to receive certain medicine or treatment plan over another medicine or the 
treatment plan 
These classifications can also be fuzzy where particular biomarkers can be both prognostic 
and predictive thus providing crucial evidence about what kind of medicine or treatment plan 
should be planned for a patient and how aggressive it should be implemented [85, 86].  
6.4.3 Pros and cons of biomarkers 
Biomarkers are definitely useful as they could lead to faster and accurate diagnosis of a 
neurodegenerative disorder. One of the biggest pros that biomarkers provide is the 
prognosis about the disease. This can also help reduce the use of animal studies and 
postmortem tissue studies [87]. The new biomarkers development has the additional 
advantages that they are non-invasive with the development of the blood based biomarkers. 
On the other hand, developing a are cost efficient biomarker is still an open field as most of 
them require huge research infrastructure to develop [88]. Another drawback is that most of 
these biomarkers are not ready for use in the clinical community as they are mainly for 
research purposes.  
6.4.4 Potential biomarkers for MCI and Alzheimer’s disease 
Both in MCI and Alzheimer’s disease, the challenge is to find a good biomarker that is 
dealing with the brain, which is the most complex organ in the body[89]. Definitely, there 
cannot be a universal biomarker for these diseases and so developing a suitable list of 
biomarkers that can cover most of the disease symptoms will be very useful [90]. Using both 
neuroimaging biomarkers and cerebrospinal fluid biomarkers, early diagnosis of Alzheimer’s 
disease is possible [91-93]. These biomarkers have shown that the levels of Aβ plaques 
arise very early in the Alzheimer’s disease pathology and then plateaus as the disease 
progresses. On the other hand, tau proteins come later and are affected by the levels of Aβ 
plaques. Using the use of these biomarkers, an accurate diagnosis of the disease state can 
be estimated along with the other clinical measurements like memory and cognitive tests. 
This provides a better understanding of the disease progression from the preclinical 
Alzheimer’s disease stage to MCI and finally into the Alzheimer’s disease [88, 94, 95].  
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6.5 Epigenetics and role of Non-coding RNAs 
6.5.1 Introduction to Epigenetics 
Epigenetics refers to the information related to the expression of the genes inherited stably 
that does not affect the primary nucleotide sequence of the DNA [96-98]. Epigenetics 
determines which genes are expressed by turning them on and off and the expression 
patterns are maintained through the cell division. Epigenetic dysregulation can lead to 
varieties of diseases by either suppressing or overexpressing certain genes. Epigenetics 
basically comprises all the chromatin and DNA modifications along with all the other 
regulatory elements that drive gene expression [99].  
 
Figure 6.5-1 Epigenetics landscape in health and disease.  
All the cell in our body has the same genome, for example, the liver cell has the same 
genome as the neurons, but clearly a different phenotype and the difference between them 
is mediated not to a large extend by epigenetic regulation [100, 101]. An interesting thing is 
that during learning, the neuron seems to take on a different epigenetic state and it again 
changes between health and disease. Since the sequence of the genome cannot be 
changed and epigenetics is reversible, there are increasing interest in epigenetic therapies 
for brain diseases that can bring back the neuron into homeostasis [102-104].  
 
There are three key epigenetic mechanisms: 
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• Histone modifications 
• DNA methylation 
• The action of non-coding RNAs 
 
Figure 6.5-2 Key epigenetics mechanisms (Adapted from Fischer et.al. [105]) 
 
These factors are there to mediate the change from environmental and genetic factors into 
long term adaptive changes. Epigenetics provides the cell the molecular toolbox to drive the 
transient stimuli into long-term adaptive changes [105].  
6.5.2 A general overview of small non-coding RNAs (sncRNAs) 
The traditional central dogma of molecular biology dictates that the DNA is transcribed to 
RNA and then translated into proteins. Small RNAs have changed the landscape and 
modified this central dogma. Out of all the genome that is transcribed, only 2% of the 
transcripts actually translated into the proteins. The remaining 98% of the non-coding 
transcribed transcripts (ncRNAs) [106] are used for the infrastructural and regulatory 
functions in the human genome [107-109].  
 
Infrastructural ncRNAs [110] include: 
• Ribosomal RNAs (rRNAs): These are the most abundant RNAs constituting about 80% 
of total RNAs. These are synthesized in the nucleolus. They are the structural and 
catalytic component of the ribosomes 
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• Transfer RNAs (tRNAs): A ~80 nucleotide (nt) long sncRNA that transfers amino acids 
to ribosomes during protein synthesis. The tRNAs are amino acid specific with each 
molecule of tRNAs consists of an anticodon that are complementary to the codon on the 
mRNA molecule [111] 
• Small nuclear RNAs (snRNAs): Performs splicing and intron removal from the primary 
transcript to form the mature mRNA transcript. It is also involved in the production of 3’ 
ends of polyA deficient histone mRNAs [112] 
• Small nucleolar RNAs (snoRNAs): Primarily involved in the processing of rRNA. These 
are encoded in introns and can be anywhere from 60 to 300nt in length [112] 
 
Regulatory ncRNAs [109, 113-115] include: 
• MicroRNAs (miRNAs): The miRNAs are about 16-27 nt in length that regulates gene 
expression post transcriptionally either by translational repression or degradation of 
mature mRNAs. They are highly conserved from plants to animals.  
• Piwi-interacting RNAs (piRNAs):  Longer than miRNAs, piRNAs are 26-32 nt long and 
mainly involved in epigenetic regulation of transcription, silencing of the transposable 
elements mainly in germ cell development and post-transcriptional gene silencing 
• Small interfering RNAs (siRNAs): Similar to miRNAs and are about 19-25 nt in length 
which are involved in the degradation of the mRNA 
• Long non-coding RNAs (lncRNAs): These noncoding RNAs ranges from several 
hundred nucleotides to several thousand nucleotides. They are involved in both 
transcriptional and post transcriptional regulation, chromatin remodeling,  and genomic 
imprinting 
 
Other ncRNAs include: 
• Enhancer RNAs (eRNAs): These are a few hundred to about 1000 nucleotides long. 
They are involved in the transcriptional regulation by acting as transcription activators 
and can be used as the markers for enhancer identification [116, 117] 
• Promoter associated RNAs (PARs): These are about 20 to 200 nt long. They are mostly 
involved in enhancing or blocking the transcription of neighboring genes and resides in 
the vicinity of the basal promoter and TSS [118, 119] 
  
 Introduction  40 
6.5.3 Biogenesis of microRNAs (miRNAs) and piRNAs 
6.5.3.1 miRNAs biogenesis 
Gene regulation is important as they make cells different from each other since the genome 
of each cell is the same. miRNAs are regulating a lot of these genes. The biogenesis starts 
with the key proteins AGO, Drosha and Dicer. PolII polymerase transcribes the miRNAs as a 
part of a much larger transcript, which happens in the nucleus (Figure 6.5-3). Then the 
Drosha cleaves the hairpin just one helical turn from the base of the hairpin. That releases 
the pre-miRNA hairpin which is then transported out of the nucleus by the exportin 5 
complexes. In the cytoplasm, dicer cleaves the hairpin loop of the pre-miRNA to form a 
miRNA duplex and from there it is loaded onto a silencing complex containing AGO protein 
which is then used to target the mature mRNAs for silencing [120]. 
  
Figure 6.5-3 miRNA biogenesis (Adapted from Devaux et.al. [121]) 
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6.5.3.2 piRNA biogenesis 
piRNAs although best characterized in the Drosophila but recent developments in the field 
have[122-124] provided more understanding about them in the mammals . The biogenesis 
starts from the transcription of the transposon or repeat elements containing uni- or bi-
directional promoters that are clustered or separated throughout the genome. This 
transcription produces piRNA precursors which are transported out of the nucleus. First, the 
longer precursors are cleaved to the length of 26-32 nucleotides in primary processing 
(Figure 6.5-4 A). From there they are loaded onto PIWI proteins in secondary processing 
which is also known as ping-pong amplification where piRNAs are amplified (Figure 6.5-4 B) 
and used for silencing [125].  
 
 
Figure 6.5-4 The biogenesis of piRNAs (Adapted from Watanabe & Lin et.al. (2014) [125]) 
6.5.4 Role of miRNAs and piRNAs in Alzheimer’s disease 
miRNAs and piRNAs although do not code for proteins themselves, but they play an 
important role in many biological processes by regulating the expression of the genes. The 
two hallmarks of Alzheimer’s disease pathology are Aβ plaques and neurofibrillary tangles. 
The Aβ plaques are formed by the increased level of BACE1 protein and many miRNAs are 
found to be associated with the regulation of the BACE1 protein levels [126]. The second 
hallmark is the neurofibrillary tangles which are formed by the hyperphosphorylated tau 
proteins. miRNAs also affects the phosphorylation of these tau proteins [127]. The role of 
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piRNAs is still not well known. The reduction in the piRNAs expression in Alzheimer’s 
disease is also linked to increase neuronal death as they drive transposable element 
dysregulation in tauopathy. piRNAs can also play a big role as a potential biomarker as the 
level of piRNAs are found to be upregulated in Alzheimer’s disease patients compared to the 
healthy controls [122, 128]. 
6.6 Machine learning in biomarker development 
6.6.1 Overview of machine learning 
Machine learning [129] and big data are the two most powerful things in healthcare in 
today’s world and revolutionized the field completely [130]. Machine learning is developing 
algorithms and code that can teach computer tasks over a period of time either from the 
gathered data or by interactively interacting with the environment. The digitization of the 
medical records has boosted the field by providing a huge amount of data which can be 
used to train and test the performance of the algorithms to better understand a disease 
mechanism [131, 132].  
 
 
Figure 6.6-1 A typical machine learning application used in biological data analysis (Adapted 
from Camacho et.al. (2018) [133]) 
 
Here (Figure 6.6-1) different type of data is collected over time, including several samples for 
genes, proteins and metabolites and other data related to the correlation between them 
[133]. Depending on the type of data, whether it is labeled or unlabeled, a suitable machine 
learning algorithm will be chosen. For unsupervised learning, an example would be the 
dimensionality reduction algorithm PCA or clustering algorithm can be chosen. In case of 
supervised learning where the labels of the data are available and depending on the 
biological question, classification or prediction algorithm will be chosen. The machine 
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learning algorithm will output a model which will be validated on an untouched test dataset 
and depending on the performance of the test, the process will be either repeated to get 
better performance of the model are being used in the clinics and hospital for the purpose of 
diagnosis or prognosis of a disease [130, 134]. 
6.6.2 Types of learning 
6.6.2.1 Supervised learning 
There are mainly three different classes of machine learning algorithms, supervised, 
unsupervised and semi-supervised learning algorithms [135-137]. In supervised learning, the 
data is provided along with the labels where the data contains the dependent variables and 
the labels will be the independent variables. It can be used either for classification or 
prediction [138]. These algorithms typically require training data and training labels which the 
algorithm will learn and build a model and then measure the performance of the learning 
algorithm on the completely untouched test dataset and test labels [139, 140]. The main 
advantage is that these algorithms can directly be measured in terms of their performance 
and outputs a numerical measure on the accuracy and inaccuracy of these machine learning 
algorithms.  
6.6.2.2 Unsupervised learning 
On the other hand, unsupervised learning has no goals to predict or to classify the data, but 
mostly used to learn more about the data [141]. Basically trying to understand the underlying 
structure in the data or uncover some unusual patterns in the data. These algorithms do not 
require labeled data. The evaluations of these algorithms are also different in terms that 
there is no way of telling how accurate or inaccurate the algorithms are because there is no 
labeled data available. There are two kinds of evaluation that can be performed for these 
algorithms, indirect or qualitative evaluations. Qualitative evaluation is measured by looking 
at the results of the algorithms and seeing something relevant in the result that helps in the 
understanding of the data [142]. On the other hand, indirect evaluation is measured by 
providing the output of the unsupervised learning algorithm to some other algorithm and 
checking if the other algorithm has performed well or not.  
6.6.2.3 Semi-supervised learning 
Semi-supervised learning algorithms are the middle ground between supervised and 
unsupervised learning algorithms [136]. These are very useful when obtaining the labeled 
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data for supervised learning is expensive, but obtaining the unlabeled data is cheap. Semi-
supervised learning data is a mix of supervised learning data, i.e. the labeled data and 
unsupervised learning data i.e. the unlabeled data. The algorithm first starts only with the 
labeled data and then used on the unlabeled data to find the tentative labels which can be 
then used to improve the performance of the model. This can be then repeated again and 
again until the algorithm converges [134]. At this point, the model is generated which is more 
accurate and used only a small amount of labeled data and the generated the labels for the 
unlabeled data.  
6.6.3 Alternative categorization of learning algorithms 
6.6.3.1 Generative learning 
Generative learning algorithms use some characteristics of the population where it finds a 
distribution for each class and creates the model for each of them separately[143]. In a 
classification problem, the algorithm will try to find a boundary where it will choose a model 
that is more plausible than the other. These algorithms are mostly probabilistic [144] and can 
be implemented using both labeled and unlabeled data for estimating the overall distribution 
of the data [145, 146].  
6.6.3.2 Discriminative learning 
Discriminative learning algorithms focus mainly on finding the boundary between the two 
classes [147]. These boundaries can be linear or non-linear in nature. These algorithms do 
not penalize for the variance of the data. The variance can be very high or low and the 
algorithm will perform the same way if the boundary is found. It uses only the points that are 
closest to the boundary to make the decisions [148].  Basically, a lot of data can be ignored, 
including precious labeled data and focus on the important data which are used to identify 
the boundary. These algorithms are very powerful when there is plenty of training data but 
can only make use of the labeled data. These algorithms cannot be used for unsupervised 
learning [149].  
6.6.4 Prior knowledge in learning 
The machine learning algorithms cannot always provide better performance. In the absence 
of a huge amount of training data, the model cannot be created perfectly and the 
performance of the model would not be adequate. Incorporating some prior knowledge into 
the learning algorithm can improve the performance where the training data is limited and 
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the algorithm does not need to make deductions about the data from the training data itself 
[150]. The prior knowledge can be incorporated into a regularization function where many 
computationally efficient approaches are there to handle the knowledge [151-153].  
6.6.5 Handling heterogeneous data 
The data in today’s research comes from various fields [154]. This introduces a new 
challenge as most of the data have different structure and different meaning. The 
heterogeneity of the data is a major challenge in this field [155]. This type of data can be 
anything starting from a free text to proper continuous data, images, codes, etc. [156]. The 
data are inaccurate and contains a lot of missing points. The data can be very dynamic and 
may evolve over time also [157].  
6.6.6 Data munging and normalization 
6.6.6.1 Data munging and wrangling 
Data munging, which is also known as data wrangling is basically the process of preparing 
datasets for the data analysis [158]. A general rule of thumb in the data analysis is the 80/20 
rule where the 80% of the time is spent in cleaning and formatting the data into the right 
format and the remaining 20% of the time is used for the actual data analysis. One important 
aspect is the use of standard data formats. There are many accepted standard available 
now, for example, CSV, TSV, XML, JSON and structured query language files. Another 
critical step is cleaning the data [159]. The obtained data can have both errors and artifacts 
that need to be removed or properly handled. Errors can be noise in the data that happened 
during the time of the data acquisition, which cannot be corrected in the data analysis step. 
On the other hand, artifacts are problems that are generated during processing and during 
the handling of the data systematically [160, 161].   
6.6.6.2 Data normalization 
In biological datasets, the data normally represent some biological phenomenon, but this is 
not the case most of the time. Along with the underlying biological or true variance in the 
data, there is also non-biological variances in the data that are the artifacts of the data and 
should be removed or normalized [162].  For example, in the microarray data, an artifact can 
be dye biases that are resulting from the overall spot intensity or location on the array [163]. 
In the RNAseq experiment, these artifacts can be the sequencing biases or GC content 
biases or unknown biases introduced during the library preparation [164]. The normalization 
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process is used to remove the non-biological sources of variation which allows comparing 
results from multiple samples.  All the downstream analysis depends critically upon this step 
as using raw data or improper normalized data can provide misleading or completely wrong 
conclusions [165-167].  
6.6.7 Random forest and other machine learning algorithms used in 
the analysis 
With the advent of next generation sequencing (NGS), there is a huge influx of big data in 
the field of biology, which led to the development of new methods and techniques to 
process, analyze and visualize the data. Machine learning algorithms are one of the key 
classes of algorithms that are very useful with this kind of data. Both supervised and 
unsupervised methods are useful. The supervised methods can use the already existing 
labels for the biological data and can start to classify the data or perform prediction on new 
samples. One goal of these algorithms is to learn from the data and generate a model with 
high accuracy performance. This performance can further be increased by combining many 
learning models where the inherent noisy and unbiased models can create a new and better 
model with low variance. This is the main concept behind random forest (RF) algorithm [168, 
169]. 
  
Random forest algorithm offers many advantages over many other machine learning 
algorithms like support vector machines (SVMs), k-nearest neighbors (KNNs), neural 
networks (NNs), logistic regression and many more [170]. RF does not overfit the data 
easily, has high accuracy, can be implemented in parallel for faster computing and provides 
variable importance information which can be extremely useful in narrowing down the big list 
of features that contain only a few informative features to a small list of useful and 
informative features [171, 172].  
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Figure 6.6-2 Schematic diagram of internal working of RF algorithm 
 
RF is basically a bagging of de-correlated decision trees [173, 174]. The algorithms work on 
𝑖 iteration by selected 𝐵 bootstrap samples of size 𝑠 from the original training dataset 
𝑀 = 〈(m1, n1), … , (mk, nk)〉  
The random forest then grows the de-correlated tree 𝑇𝑖  to these bootstrap sampled datasets 
(𝐵). At the end of 𝑖 iterations, ensembles of all de-correlated decision trees are returned.  
Prediction is done by calculating the average of all predictions of all decision trees. 
Classification, on the other hand, is done by taking the majority vote of all single tree 
predictions (Figure 6.6-2). 
6.6.8 Feature selection 
It is a common knowledge in the field of machine learning that the performance of a given 
machine learning algorithm heavily depends on the quality and quantity of the features 
provided to the algorithm. Finding and selecting a good feature is a challenging task [175]. 
Features contain information related to the target variables. In a classification problem, 
features should provide the information on the available labels and the classification model 
will be defined in terms of these features [176]. This leads to a misunderstanding as 
including more features does not provide the algorithm a better discriminative power [177]. In 
healthcare (clinics) field getting patient data is expensive. With the limited amount of 
samples and a huge number of parameters (features) that can be measured in these 
samples, developing a machine learning algorithm is not an easy task [178]. The algorithm’s 
performance decreases as the amount of feature grow (Figure 6.6-3) [179].  
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Figure 6.6-3 Relationship between a machine learning algorithm's performance and the 
number of features  
This is due to the presence of irrelevant features which introduces noise in the data and 
redundant features that do not provide any additional information which degrades the 
performance of the learning algorithm. This curse of dimensionality is very problematic with 
limited training examples (clinical data, genomic and epigenomic datasets etc.) [179] and 
also limited computational resources as it increases the search space and ultimately this 
leads to overfitting. Thus, it becomes very important to perform feature reduction before 
training a learning algorithm. There are two types: 
• Feature selection: is selecting a smaller subset of the features from a larger set of 
features 
• Given a big set of features F = {x1, x2, …, xN} that contains both relevant, irrelevant and 
redundant features, a smaller set of relevant features F’⊂ F = {x1′, x2′, …, xM′} that 
optimizes the learning algorithm for better performance 
• Feature extraction: is the process of transforming or projecting the original set of 
features (N) into a higher dimensional plane with a reduced number of dimensions (M) 
 
The final goal is to either improve or maintain the learning algorithm’s performance by 
possibly simplifying the algorithm’s complexity (Figure 6.6-4).  
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Figure 6.6-4 Modified relationship between a machine learning algorithm's performance and 
the number of features 
6.6.9 Evaluation of learning models 
A good machine learning algorithm not only uses fewer resources, but should also perform 
well during the evaluation phase. This is important as these algorithms are going to be used 
on unseen and unlabeled data points for classification and prediction. There are many 
choices for the performance evaluation of these learning algorithms. In supervised learning, 
there are classifications and regression evaluation metrics while unsupervised learning has 
their own metrics.  
6.6.9.1 Classification metrics 
Typical choices for performance evaluation for classification models [180] include: 
Table 6-2 Common classification metrices [181-183] 
Metrics Description 
Accuracy 
• Most common and misused evaluation metric 
• It is basically the ratio of true predictions over total predictions 
• It is not suitable for imbalanced classes 
• The predictions or classifications are binary in nature as they 
assign each prediction or classification with either 0 or 1 
Logarithmic Loss  
• Also known as logloss which takes the uncertainty of predictions 
or classification into account 
• It is calculated by measuring the accuracy after penalizing the 
false classifications  
• The probability of each class has to be defined before the 
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evaluation 
Confusion Matrix 
• Useful for multi-class classification problems 
• It is represented in the form of a table where rows represent 
actual class and column represents the predicted class 
Precision-Recall 
• Precision represents the exactness of the model and calculated 
as a percentage of predicted positives are actually positive 
• The Recall represents the completeness of the model and 
calculated as the total positives labeled by the model 
• It is useful with the imbalanced classes 
Area Under ROC 
Curve [184] 
• Is commonly known as AUROC (Area Under the Receiver 
Operating Characteristic curve) 
• Provides both aggregated accuracy of AUC and true positive 
rates vs. false positive rates (ROC) with the variation in 
classification threshold 
• It also provides a good visual summary of the performance of the 
model 
6.6.9.2 Regression metrics 
Table 6-3 Common regression metrices [185-189] 
Metrics Description 
Mean Absolute Error 
• Also known as MAE and is calculated by averaging the absolute 
difference of each prediction of actual values 
• It provides a sense of the magnitude of the error and it is also less 
sensitive to outliers 
• It has the same unit as the original data 
Mean Squared Error 
• Also known as MSE and is calculated by averaging the squares of 
the difference of each prediction to actual values 
• It is sensitive to large outliers 
• Can be used in the comparisons of various statistical models 
R squared (r2) 
• Also known as the coefficient of determination and provides 
information on how good the predictions are compared to the 
actual values 
• It represents the amount of variation in the independent variable 
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that can be explained by the variance in the dependent variable 
• The values lie between 0 and 1 
 
6.6.9.3 Unsupervised learning metrics 
Evaluation of an unsupervised learning algorithm is a difficult task compared to the 
supervised learning evaluation. It varies mostly subjective as the definition of success with 
those algorithms on the basis of the question being asked. One of the most common 
categories of unsupervised learning algorithms is clustering algorithms [190, 191]. There are 
mainly two types of cluster validity measurements: 
• Extrinsic or external index: The clustering performance is measured indirectly on the 
basis of another learning algorithm (mostly supervised learning)  where a good 
performance of supervised learning algorithms reflects a good clustering of the data 
points 
• Intrinsic or internal index: The clustering performance is measured as to how well the 
clusters are by themselves without the use of any external input. It can be qualitative 
where the clustering is helpful in the understanding of the data 
Apart from the above mentioned criteria [192, 193], unsupervised learning can also be 
evaluated using other evaluation metrics like Rand index, F-score and Mutual information 
[194].  
6.7 Three dimensional organization of the genome 
6.7.1 General features of the 3D genome organization 
One of the most pressing questions in molecular biology was the organization of the DNA 
into the nucleus as the spatial organization and position of the genes and other regulatory 
elements drive the expression of these genes and any misregulation may result in a disease 
or disorder [195, 196]. Another question was how does the same genome result in so many 
different cell types in the body [197]? Biochemical elements like promoters, enhancers, and 
insulators are known for a long time now where promoters are normally the starting point of 
the transcription, enhancers controlling the rate of transcription and insulators controls which 
gene an enhancer can target [198]. At the smallest scale (Figure 6.7-1) [199] DNA is 
wrapped around the histone octamers also known as nucleosomes and at the highest scale, 
i.e. at the chromosome level scale each chromosome occupies a unique territory within the 
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nucleus [200, 201]. The intermediate steps in between are now being studied and the 
characterization of their functions is showing up.   
 
 
Figure 6.7-1 Common organizational structures in the genome adapted from Szalaj et.al 
(2018) [199]  
6.7.1.1 Chromosome territories 
The knowledge of chromosome territories (CTs) has been known more than a century. The 
chromatin in a non-dividing cell are known to occupy a certain place in the nucleus  where 
chromosomes with high gene density tends to cluster together with an inclination towards 
the center of the nucleus while gene poor chromosomes [202] co-occupy the regions that 
are at the boundary of the nucleus.   
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Figure 6.7-2 Chromosome territories (Adapted from Bolzer et.al. (2005) [203])  
Figure 6.7-2 is portraying a spectral karyotyping where each chromosome is artificially 
labeled with different colors where they occupy their own territories [203].  They are around 
50 – 250Mb in length. A common method of detection is Fluorescence In Situ Hybridization 
(FISH). 
6.7.1.2 Compartments 
The mammalian genomes have another level of organization in terms of active and inactive 
compartments [202, 204, 205]. The active compartment tends to interact with respective 
active compartments and an inactive compartment tends to interact with their respective 
inactive compartments [206]. The interactions between the active and inactive compartments 
are minimal. There is another observation that the active compartments have higher gene 
expressions compared to the inactive compartments where the gene expression is generally 
silenced [207]. However, the mechanism on how the compartments are formed or what 
constitutes an active compartment and what constitutes as inactive compartments is still 
unknown. Recent studies have shown that there are now at least 6 subcompartments [208].  
6.7.1.3 TADs 
Zooming into the specific compartment around 100 KB resolutions (Figure 6.7-1), there are 
different domains which are not alternating but more are domains. These domains are called 
topologically associating domains (TADs) [209, 210]. These were one of the biggest 
discoveries as a big black box in chromatin organization can be explained with TADs [211]. 
Genomic elements within the same TAD interact with each other, but they do not tend to 
interact with the genomic elements located in different TADs. These TADs are cell type 
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invariant. On average, TADs ranges from a few hundred KBs to several hundred MBs. The 
distributions of genomic elements have a specific pattern inside the TADs. Gene promoters, 
promoter associated histone marks such as H3K4me3 and insulator marks are tending to 
stay on the boundary of the toads while enhancer elements like H3K4me1 are spread all 
along the TAD. The boundary regions are especially enriched with insulator proteins like 
CTCF along with repeats and housekeeping genes [212, 213].  
6.7.1.4 subTADs 
Initially TADs are considered as cell type invariant and conserved across the species. This is 
still unclear as upto how much these domains are conserved. Although TADs are cell type 
invariant, the subdomains also known as subTADs are found to be cell type specific [214]. 
These subTADs are the domains where a specific regulatory mark like a promoter or 
enhancer can be co-regulated [215].  
6.7.1.5 Chromatin Loops 
The human genome is subpartitioned into approximately ten thousand loops [216]. Loops 
are basically two regions of chromatin that are linearly far apart but close to each other in 
3D. On average, loops are approximately 200kb in length and do not overlap with each other 
(Figure 6.7-1). This is one of the mechanisms to control gene expression [217]. The TSS 
and enhancer loop each other which express a gene. Loops are primarily formed by the 
binding of CTCF proteins to their respective motif binding sites which occurs at the boundary 
of the loops [218]. Recent studies have shown that the CTCF motifs that are involved in the 
formation of loops should be pointing towards one another [219-221].  
6.7.2 Tools to explore 3D genome organization 
The three dimensional organization of the genome can be understood from different 
approaches. Mainly NSG bases techniques and imaging techniques [222] are used to 
visualize these chromatin structures and DNA editing tools like CRISPR-Cas9 for the 
functional understating of the genome [223, 224].  
6.7.2.1 Imaging based tools 
Imaging tools helps to view the chromatin structures and to study the organization of 
genomic elements. Among the various techniques that are used these days to quantify the 
distances between elements and view the structures, some are: 
• Fluorescence in situ hybridization (FISH) [225] 
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• MB-FISH (Molecular Beacon-FISH) [226] 
• Super-resolution dipole orientation mapping (SDOM) microscopy [227] 
• Low-power super-resolution STED nanoscopy [228] 
• Cryo-electron microscopy (cryo-EM) [229] 
6.7.2.2 3C-based technologies 
The emergence of 3C (Chromosome Conformation Capture) [230] based techniques has 
revolutionized the field of three dimensional genome organization.  After the advent of the 
first 3C technique, many other variations have emerged. Some of them are:  
• Chromosome conformation capture-on-Chip (4C) [231] 
• Chromosome conformation capture carbon copy (5C) [232] 
• 3C-chip [233] 
• Combined 3C-ChIP-Cloning (6C) [234] 
• Chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) [235] 
• Hi-C [236] 
• Capture-C [237] 
6.7.3 Role of 3D genome organization in diseases 
In the healthy state of an individual, the three dimensional organization of the genome into 
proper domains and loops occur normally. Any disruptions in this organization results in the 
misregulation of the genomic elements causing disorder and diseases [238, 239]. In a 
healthy state the regulation of gene expression is controlled by restricting the enhancer 
promoter interactions to their domains. Disruptions in the boundaries of these domains 
(TADs) have shown to cause gene expression changes where an enhancer from one TAD 
can influence the expression of a gene in a different TAD. This can lead to various disorders 
like Schizophrenia, various types of cancer, etc. [240]. They are also linked to physical 
deformities like the F syndrome or Autosomal-dominant adult-onset demyelinating 
Leukodystrophy (ADLD). Developing a better understanding of these gene regulation can 
help understand the disease mechanism and provide the understanding on how they causes 
the pathogenic phenotypes [241, 242].  
 
  
 Objectives  56 
7.   Objectives 
The tight control of gene expression programs in the adult brain is critical for synaptic 
plasticity and memory formation. Epigenetic mechanisms [243, 244] are key processes that 
control gene expression at a systems level. There is emerging evidence that dynamic 
changes in histone modifications, DNA methylation/demethylation, and the expression of 
small noncoding RNAs provide brain cells a cellular and molecular toolkit by which 
environmental stimuli are transformed into long-term adaptive changes. In fact, epigenetic 
processes have been linked to synaptic plasticity and memory function and have emerged 
as promising novel therapeutic approaches to treat neuropsychiatric and neurodegenerative 
diseases [105]. These findings, however, are mechanistically not well understood. In almost 
over a decade, say from 2007, the new field of neuroepigenetics [245] has emerged, but the 
base publications in the field dated back to more than four decades ago [38]. During this 
time, although there has been tremendous development in technologies and discoveries of 
novel biomarker development, but there is a distinct lack of mechanistic insights.  
 
An important question that has so far not been addressed is how do neurons change their 
epigenome in a neuronal network? With this broader question in mind which I may not find 
an answer during my Ph.D., I am hoping to solve a part of the question by working on two 
aims which are described below. 
 
Aim1:  To study the epigenetic regulation of information in a neuronal network like exosomal 
transfer of small noncoding RNAs that may lead to the development of the new category of 
biomarkers for neurodegenerative disease especially focusing on Alzheimer’s disease 
• The main hypothesis for this aim is that the small noncoding RNAome measured in 
the brain, CSF and blood may be used to detect biomarker signatures for 
neurodegenerative disorders 
• First, use the high throughput next generation sequencing (NGS) techniques to 
quantify the expression of small noncoding RNAs in Alzheimer’s disease patients and 
their respective control samples 
• Then, develop targeted statistical and machine learning pipeline and tool kits to 
process the NGS data to identify informative and putative biomarker signatures 
• Finally, test the performance of these small noncoding RNAs signatures in different 
replication cohorts for: 
o Disease diagnosis, i.e. to classify Alzheimer’s disease patients from their 
respective controls with high precision and accuracy 
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o Disease onset, i.e. predict the conversion of some of the patients suffering 
from mild cognitive impairment to develop Alzheimer’s disease in due course 
of time 
• Perform the comparison of the performance of these small noncoding RNAs 
signatures to the existing clinical protein biomarkers 
 
Aim2:  To study the role of dynamic changes in higher order chromatin structure that control 
gene expression programs in neuronal plasticity 
• Understand the three dimensional (3D) organization of the genome inside neuronal 
and non-neuronal cells and its impact on the regulatory network using Chromosome 
Conformation Capture (3C) [230, 246] based techniques like 5C [232, 247], Hi-C 
[236] and 3C-seq [248] 
• The hypothesis is that the dynamic changes in higher order chromatin structure 
control gene expression [249] programs in synaptic plasticity, memory function, and 
neurodegenerative disorders 
• First, in a pilot project, the epigenome organization and higher order chromatin 
structures in FACS sorted non-neuronal and neuronal nuclei from the hippocampal 
region (CA1) under the naïve condition will be studied in C57BL/6J wild type mice 
using 3C-seq technique 
• Then, with the help of publicly available existing tools and if needed, develop new 
pipelines to identify long-range looping interactions and topologically associating 
domains (TADs) in neurons and non-neurons 
• Perform comparisons in the looping patterns in neuronal/non-neuronal interactions 
and domains and also identify few important differences related to the deregulation of 
the genes that may be involved in neurodegenerative disorders like Alzheimer’s 
disease 
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8.   Materials and methods 
8.1 Cerebrospinal fluid (CSF) from humans 
8.1.1 CSF from Alzheimer’s disease patients and control humans 
Cerebrospinal fluid was collected by performing a lumbar puncture (spinal tap) on 82 control 
humans (nonAD), 42 Alzheimer’s disease patients, 11 mciStable and 6 mciAD patients. The 
procedure was performed after the approval of Institutional review board (IRB) of Dept. of 
Medical Ethics and History of Medicine at University Medical Center Göttingen (IRB 
02/05/09). The samples were collected at the University Medical Center Göttingen 
(Germany), Department of Psychiatry, Göttingen (Germany), University Department of 
Neurology at Universitätsklinikum Tübingen (Germany) and Paracelsus Elena clinic Kassel 
(Germany). The samples were collected from Jan 2012 and Mar 2013 and from Apr 2013 
and Oct 2014. Standard operating protocols were applied during the collection and handling 
of the CSF from the individuals. 5 to 10 mL CSF was collected in 4 vials and protease 
inhibitors and preservative were added to the collected CSF. It was then centrifuged for 10 
mins at 2000 x g at room temperature to get rid of extra membrane fragments or cell debris. 
The resulting supernatant was flash frozen and stored in a minus 80°C freezer for the 
extraction of RNA from the exosomes.  
8.1.2 Extraction of CSF exosomes 
The flash frozen supernatant was removed from the minus 80°C and centrifuged three times 
at 4°C. First centrifugation was performed for 10 mins at 3500 x g and the supernatant was 
then centrifuged again for 10 mins at 4500 x g and the resultant supernatant was then 
centrifuged again for 30 mins at 10000 x g. The supernatant was then further subjected to 
ultracentrifugation for 10 mins at 100000 x g resulting in an exosomal and exosomal-free 
fraction which was then resuspended in 0.2ml TRI Reagent® (RNA Isolation Reagent from 
Merck). The exosomal fraction was then stored at minus 80°C freezer prior to RNA isolation.   
8.1.3 Total RNA isolation 
The exosomal fraction was homogenized with 1ml of TRI Reagent® (RNA Isolation Reagent 
from Merck). 25 μl/ml of distilled H2O [diethyl pyrocarbonate (DEPC) treated and 2 μl of 
glycogen was added to the mixture and incubated for 5 mins at room temperature followed 
by the addition of 0.2 ml of phenol/chloroform. The samples were shacked vigorously and re-
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incubated for an additional 5 mins followed by 15 mins of centrifugation at 1200 x g at 4°C 
and clean transfer of phase separated aqueous RNA was carefully collected. Overnight 
precipitation of collected aqueous RNA was performed at minus 20°C with 0.5 ml 
isopropanol. The precipitated RNA was centrifuged at 4°C at 12000 x g for half hour and 
after discarding the supernatant, the isolated pallet was washed twice with 75% ethanol and 
resuspended in 10 μl of RNAse free water after air drying the RNA pellet.  
8.1.4 SmallRNA library preparation 
Small RNA libraries were prepared from total RNA using the TruSeq®(Illumina) small RNA 
sample preparation kit according to the Illumina reference guide for TruSeq Small RNA 
Library Prep Kit. Briefly, the adapters are ligated to the RNA molecules. A cDNA library is 
generated by performing reverse transcription, amplification and gel purification of adapter 
ligated RNA molecules. SmallRNA sequencing was performed on the aliquoted cDNA 
libraries.  
8.2 Processing of next generation sequencing data 
8.2.1 Generation of raw fastq files 
For the processing of the sequencing data, a customized in-house pipeline was used. First, 
the HiSeq™ 2000 Sequencing System performs image analysis and basecalling using the 
machine’s internal software provided the primary data files in the *.bcl (binary base call) 
format. Illumina's bcl2fastq (v 1.8.4) [250] with default parameters was used to convert the 
base calls in the per-cycle BCL files to the per-read FASTQ format. Along with the 
conversion of base calls *.fastq reads, demultiplexing of the samples are also performed in 
parallel using the same Illumina's bcl2fastq (v 1.8.4) software with default parameters.  
8.2.2 Quality control (QC) for raw sequencing data 
Basic quality control for each generated *.fastq files was performed with illumine_qc.sh (v 
1.2.0) [251] with default parameters which produced fastq_screen plots for an overview of 
sequencing quality. If the samples pass the quality control step, they are stored in the DZNE 
[252] long term storage file server and can be used for further analysis. Before the transfer to 
the long term storage from the local Illumina machine storage, the MD5 checksums of all the 
*.fastq files and the directory are generated using md5checker.py (v 0.3.2) with default 
parameters.  
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8.3 SmallRNA mapping pipeline (GJSrMap) 
The smallRNAs mapping pipeline (GJSrMap) (v 2.5.0) [253] was used to align all the *.fastq 
files. All the following steps were performed on the GWDG’s high performance computing 
cluster (HPCC) [254] using gwdu103.gwdg.de as the master node. The jobs were launched 
on to short or long queues with a maximum of 12 cores, maximum time constraint of 24 
hours and maximum memory constraint of 16GB using FAT queue. The average run time of 
each job is approximately 13.58 mins, average memory used was 171.2 MB and average 
max threads were 26.75.  
 
The mapping is performed in the iterative manner. First all the relevant files are downloaded 
and processed for the reference genome (Table 8-1). We trim low-quality ends from reads 
before adapter removal having Phred quality score [255] less than or equal to 28. We then 
trim the 3' adapters and filter out the reads with the minimum length of 15 nucleotides. We 
first map the reads to the reference genome created from microRNA and piRNA sequences. 
Reads greater than 33bp were mapped to the reference genome created by other small non-
coding RNA. Remaining unmapped reads were then mapped to the human genome.  
 
We used bowtie [256] for all the reads alignment o the reference genome. We allowed no 
mismatches for the first part of the mapping and one mismatch for the rest of the mapping. 
Read count distribution and visualization was generated using in-house python script. Final 
data, summary and QC is collected as shown in (Figure 8.3-2 A and B) 
 
 
 Materials and methods  61 
Figure 8.3-1 The smallRNA mapping pipeline (GJSrMap) [253] 
8.3.1 Prepare custom reference genome 
The smallRNAs reads are aligned to the custom reference genome made from the small 
noncoding RNA sequences and also to the reference human genome sequence. This is to 
avoid the problems of multiple mapped reads and to increase the sensitivity of the mapping.  
 
Table 8-1 Description of small noncoding RNAs using in the mapping 
smallRNAs  Description 
miRNA Mature microRNA 
piRNA Piwi-interacting RNA 
rRNA Ribosomal RNA 
scRNA Small cytoplasmic RNA 
snRNA Small nuclear RNA 
snoRNA Small nucleolar RNA 





Other small noncoding RNA 
     - Transfer RNA 
     - Transfer RNA located in the mitochondrial genome 
     - Miscellaneous other RNA 
8.3.1.1 Small noncoding RNA and full genome sequences source 
Human precursor and mature miRNA sequences are downloaded from miRBase [257] 
(version.20) with genome-build-id: GRCh37.p5 and genome-build-accession:  
NCBI_Assembly:GCA_000001405.6.   
 
Human piRNAs sequences are downloaded from piRNABank [258] 
(http://pirnabank.ibab.ac.in/index.shtml).   
 
Human other small noncoding RNAs were downloaded from EnsEMBL release 75 - 




 Materials and methods  62 
The assembly of the human genome (hg19, GRCh37 Genome Reference Consortium 
Human Reference 37 (GCA_000001405.1) in Feb. 2009) as well as repeat annotations and 
GenBank sequences were downloaded from 
http://hgdownload.soe.ucsc.edu/goldenPath/hg19/bigZips and random contigs were filtered 
out using the Unix command grep [259].  
8.3.1.2 Pre-processing of the sequences 
Alignment of small noncodig RNAs is always a challenging task due to their origin from 
multiple genomic locations. In order to avoid multi-mapped reads, a custom reference 
genome is created with unique sequences of every smallRNAs. Multiple smallRNAs with 
same sequences are collapsed into the single smallRNAs with a new unique ID that is a 
combination of the individual IDs separated by a “|” symbol. This solves the problem of the 
multiple mapped reads, as there won`t be any read that needs to multi-mapped any more. It 




8.3.1.3 Custom reference genome indexes 
The custom reference genome indexes are built for the iterative steps in the pipeline. There 
are three custom reference genomes; pimiRNAs (miRNAs + piRNAs) reference genome, 
sncRNAs (all other small noncoding RNAs other than miRNAs and piRNAs) and the full 
human genome. Bowtie-build command with default parameters of the Bowtie (v 1.1.2) [256] 
alignment tool is used to build the indexes for pimiRNAs and sncRNAs. The index of the 
human genome (hg19) is downloaded from the Pre-build index library of bowtie tools 
(ftp://ftp.ccb.jhu.edu/pub/data/bowtie_indexes/hg19.ebwt.zip)  
8.3.2 Pre-processing and quality control before alignment 
8.3.2.1 Quality control for FastQ files 
At every iteration, from 0 to 3 of the iterative mapping pipeline, quality control of raw 
sequencing data is performed using FastQC (v 0.11.5) [260] using the default parameters 
and --quite option for the quite mode as the additional argument.  
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8.3.2.2 Low-quality read filtering  
Due to the shorter length of small noncoding RNAs compared to the sequencing read length, 
the sequencing adapters are also sequences which can cause a problem in the mapping as 
the partial adapter sequences do  not exists in the reference genome and hence can cause 
a very poor mapping. Before trimming the adapter sequences, low quality fastQ reads are 
removed to increase the quality of the mapping. FastQ reads having the Phred quality score 
of less than 28 encoded in ASCII33 are removed and not considered in the analysis using 
cutadapt (v 1.9.1) with the argument: 
--trim-qualities 28 or –q 28 
8.3.2.3 Adapter trimming and read size selection 
3’ adapter sequences are removed using the cutadapt (v 1.9.1) [261] and along with that two 
types of read size selection are also performed for the iterative mapping steps 1 and 2. For 
the first step, reads between 16 and 32 nucleotides are considered and for the second step, 
reads greater than 32 nucleotides are considered. Along with the adapter removal cutadapt 
also perform the size selection using the arguments: 
• --minimum-length 16 or -m 16: This option will remove any reads 
shorter than 16 nucleotides 
• --maximum-length 33 or -M 33: remove any reads greater than 33 
nucleotides 
• --too-long-output <filename>: This is the option that is set to save 
all the reads that are longer than 33 nucleotides in the same fastQ 
format 
8.3.3 Iterative mapping of the filtered fastQ reads 
This step is performed in three iterations followed by read quantification and the cleanup 
step.  
8.3.3.1 Iteration 1: mapping to pimiRNA reference genome 
The filtered fastQ reads between the size of 16 and 33 nucleotides are mapped to the 
custom pimiRNA reference genome.  The mapping is performed using bowtie (v 1.1.2) with 
fine-tuned parameters for optimal mapping.  
• -v 0 is used is set for end-to-end hits with zero mismatches to keep 
the mapping very conservative for this iteration 
• -p/--threads 4 are the number of alignment threads for faster mapping 
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• -S/--sam is set for writing all the mapped reads into the Sequence 
Alignment Map (SAM) format 
• -a/--all is set to get all alignments for every read 
• -m 1 is set to remove all alignments that have more than one 
reportable alignments 
• --un <unmapped_fastq> to save all the unmapped reads for iteration 3 
where these reads will be mapped again but to the entire human genome  
The resulting SAM files are converted to BAM (Binary SAM) files and indexed using 
samtools (v 1.3.1) [262]. This iteration is run using the “fat” queue with four maximum 
numbers of cores.  
8.3.3.2 Iteration 2: mapping to sncRNA reference genome 
The fastQ reads longer than 32 nucleotides are mapped to the custom sncRNA reference 
genome. The mapping is performed using bowtie (v 1.1.2) with same parameters except  
• -v 1 is used is set for end-to-end hits with one possible mismatch 
for a little relaxed mapping strategy 
The unmapped reads from the previous iteration 0 and current iteration 1 are then 
concatenated for the next step and saved to the file. The resulting SAM files are converted to 
BAM files and indexed using samtools (v 1.3.1). This iteration is also run using the “fat” 
queue with four maximum numbers of cores.  
8.3.3.3 Iteration 3: mapping to full genome 
The unmapped reads from both iteration 1 and iteration 2 are then mapped to the human 
genome. The mapping is performed using bowtie (v 1.1.2) with the same parameters as 
iteration 2. The resulting SAM file is converted to the BAM file. It is then concatenated with 
the BAM files from iteration 0 and iteration 1 along with the remaining unmapped fastQ reads 
in the iteration 3 and indexed using samtools (v 1.3.1). Low quality mapping reads are 
filtered using samtools with the option mapq >= 30. The final BAM file in then converted to 
the SAM file for the read counting step. This iteration 3 is run using the “fat” queue with four 
maximum numbers of cores.  
8.3.4 Read counting and summary statistics 
8.3.4.1 Read counting and summary quality control report 
Read counting is performed on the SAM file using the AWK [263] unix tool and distributing 
the counts for each smallRNA into their respective classes. Along with the raw read counts 
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distribution, normalized counts are also generated by simple RPM (reads per million) where 
the counts are divided the total uniquely mapped reads for the sample and multiplying it by 
the million. This is sufficient as smallRNAs read length distribution is narrow and hence bias 
to GC content or read length do not occur in the normalization of these reads. 
 
A summary quality control report is also generated apart from individual quality control 
reports for each iteration of the pipeline. MultiQC (v 0.9) [264] is used with default 
parameters for each iteration and also a combined QC for all the iterations. The report is 
provided in the form of plots and also HTML reports.  
8.3.4.2 Summary mapping and smallRNA statistics 
A customized python script is used to create the following mapping and smallRNA statistics 
plots. 
 
Figure 8.3-2 Sequencing quality control, mapping and smallrnaome distribution 
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Few plots are shown in Figure 8.3-2 Sequencing quality control, mapping and smallrnaome 
distribution. A. Shows the sequence quality information for 16 samples. X-axis represents 
the nucleotide position within the read and the Y-axis represents the quality scores (Phred 
score). The plot is divided into three parts according to the quality scores. The red part 
represents poor quality, orange part represents reasonable quality and the green part 
represents the good quality calls from the sequencer. The quality score  from the Illumina is 
Q scores (Q = -10log10P) [255] which is an estimate of the probability of a particular base 
being called incorrectly. The score is averaged over the entire read length and deteriorates 
towards the end of the read. A Phread quality score of 30 tells us the probability of 1 
incorrect base call for every 1000 base calls the sequencer makes. B. A barplot of uniquely 
mapped reads for each sample. On average, a quarter million reads were uniquely mapped 
to the small non-coding RNAome. One sample seems to have a failed sequencing. C. 
Representation of small non coding RNAs in serum samples. The majority of the detected 
small non coding are microRNAs covering 95% of entire small non coding RNAome. D. Top 
10 expressed miRNAs (Blue). Last bar represents an aggregate summary of remaining 
expressed microRNAs. The inset violin plot shows the distribution of entire detected 
microRNAome. Similar plots are provided for all the other smallRNAs. 
8.4 Data filtering and normalization 
 
 
Figure 8.4-1 Sample filtering, feature normalization and filtering 
All the samples with library size (total uniquely mapped reads) less than 50000 reads were 
removed from the analysis as they do not contribute valuable information to the downstream 
analysis. Samples that were less than 40 years were also removed from the analysis in 
order to maintain the uniform age distribution (Figure 8.4-1).   
 Materials and methods  67 
8.4.1 Normalization of smallRNAs 
Various normalization strategies for the miRNA and piRNA normalization were tested as 
there was no standard normalization protocol available for the smallRNAs although many 
comparison references are available [265, 266].   
 
Figure 8.4-2 Various normalization strategies 
 
The raw data after visualization was found to be pretty variable (Figure 8.4-2A).  
Quantile normalization [267, 268] aligns the count distribution of samples. The quantile 
scaling factor for ith sample  𝜑𝑖 has the form of 
𝜑𝑖
𝑞𝑞𝑞𝑞𝑞𝑖𝑞𝑞 = 10𝐿𝐿𝑔10𝑄𝑖−�1𝑁�Σ𝑗=1𝑁 log10 𝑄𝑗 
Where N is the total number of samples, 𝑄𝑖 ,𝑄𝑗 are upper quantiles of ith and jth samples. 
Figure 8.4-2 B shows the upper quantile normalization of the samples which is a lot less 
variation compared to the raw data. 
 
Median normalization [269] implemented DESeq2 which is specifically implemented for the 
negative binomial distributed counts data has the form of 
𝜑𝑖
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Where N is the total number of samples,  𝐶𝑠𝑖 , 𝐶𝑠𝑗 are the counts of smallRNA s for the ith and 
jth sample. Figure 8.4-2 C shows the median normalization of the samples which is similar to 
the quantile normalization and also has a lot less variation compared to the raw data. 
 
Variance stabilization normalization [269-273] for the negative binomial distribution is given 
by  
𝜑(𝑥)𝑉𝑉𝑉 =  𝑙𝑙𝑙�1 + 2𝑥𝛼0 + 𝛼1 + 2�𝑥𝛼0(1 + 𝑥𝛼0 + 𝛼1) �log[2]  
Where, 𝛼0,𝛼1are the two constants for dispersion 𝛼 representing asymptotic dispersion and 
extra-Poisson factor respectively.  The VST is a transformation 𝜑(𝑥)𝑉𝑉𝑉 for a random 
variable X whose variance- mean relationship is 𝜈 =  𝜇 +  𝜇2𝛼0 + 𝜇𝛼1and variance (X) is 
equal to 𝜈(𝐸(𝑋)) which makes the 𝜑(𝑥)𝑉𝑉𝑉 homoscedastic. 
 
Figure 8.4-2 D shows the VSN of the samples which is a lot less variation compared to the 
raw data and other transformation and used for all the downstream analysis. The VSN 
counts were also corrected for cohort effects as the samples were collected from multiple 
centers along with the removal of the unwanted variances using the R (v 3.2.2)[274] 
package RUVSeq (v 1.14.0) [164].  
8.4.2 Filtering of non-expressed smallRNAs 
miRNAs and piRNAs having variance stabilized normalized (VSN) read counts of least 0.5 in 
the 95% of Alzheimer’s disease and control samples separately were considered as 
expressed smallRNAs (Figure 8.4-1). We performed the filtering on miRNAs and piRNAs 
obtaining a set of 154 expressed miRNAs and 43 expressed piRNAs and were considered 
for further analysis.  
8.5 Statistical and machine learning analysis 
Due to the low number of samples and high number of features, various statistical and 
machine learning methods are applied to reduce the number of uninformative features and 
get a list of informative features that can be used as a potential signature for biomarkers.  
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Figure 8.5-1 Feature selection 
 
In order to obtain informative miRNAs (154) and piRNAs (43), “Measure of Relevance (MoR) 
procedure [275] on 61 samples of cohort 1 was applied. Considering high dimensionality of 
the features compared to a very small set of samples, the MoR procedure can reduce 
features set to small informative features set by evaluating distribution overlap (assuming 
that samples are independent), biological difference, dispersion parameters of the samples 
and weighing factor common to all features. The 𝑀𝑙𝑅𝑗 value for jth smallRNA feature is 
given by: 
𝑀𝑙𝑅𝑗 = 1


















Where, 𝑛1,𝑛2 are two sub samples from N, p shows all smallRNA features and 𝑝𝑗 represents 
jth feature, 𝑈�1
𝑗 ,𝑈�2𝑗, 𝑠𝑈𝑘1𝑗2 , 𝑠𝑈𝑘2𝑗2 , 𝑠𝑈𝑘1𝑗 𝑈𝑘2𝑗 represents means, variances and covariance of rank 
transformed values of jth smallRNA feature for two sub samples 1 and 2.  
The absolute MoR values for each feature are then sorted in decreasing order and a suitable 
selection and evaluation criterion is applied to the information chain as described in [275]. 
We also applied reliability analysis (RiA) [276] to obtain a reduced set of informative features 
by applying MoR procedure (500 iterations) to a randomly selected subgroup of samples and 
features and features with a relative frequency higher than 0.25 during 500 iterations were 
selected. We chose features that were common between MoR and RiA as reliable features 
for further analysis. 
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Figure 8.5-2 miRNAs and piRNAs 
 
8.5.1 Variable ranking and removal of low ranked variables 
Given the very low number of samples, the reliable features were further ranked [277] by 
sorting the features according to some scoring function 𝑆(𝑖) values given by [188, 278]: 
𝑆(𝑖):𝐹 →  Ω 
Where, 𝑆(𝑖) is the scoring function computed from the values of training data with a set of 
features 𝐹 =  (𝐹1, … ,𝐹𝑞) and Ω is the probability space which is the set of possible 
classifications{𝑐1, … , 𝑐𝑞}. 
 
A combination of various machine learning algorithms were used and the mean score was 
calculated from the scoring functions which were used to rank the reliable features.  
 
First, Ridge regression [279] which is also known as Tikhonov regularization was used. Here 
the loss function is a linear least squares function with l2 regularization. The linear least 
square function is calculated using singular value decomposition (SVD) on the input matrix 
𝑀(𝑛,𝑝) with the complexity of 𝑂(𝑛𝑝2) where𝑛 ≥ 𝑝. The ridge algorithm with default 
parameter given by  
Ridge(alpha=0.5, copy_X=True, fit_intercept=True, max_iter=None, 
normalize=False, random_state=None, solver='auto', tol=0.001) 
is used. The output are the coefficients which the Ridge algorithm minimized by applying a 
penalty on the size of the coefficients (the residual sum of squares). The minimization 
function is given by 
 




2 + 𝛼‖𝑀‖22  
 
Where, 𝛼 is the regularization strength, 𝑦 is the output variable and 𝑀 are the coefficients of 
the linear model. 
 
Along with the Ridge, where l2 regularization parameters are set, Bayesian regression can 
estimate these parameters by fine tuning from the data. Bayesian Ridge [280-283] 
regression given by  
BayesianRidge(alpha_1=1e-06, alpha_2=1e-06, compute_score=False, 
copy_X=True, fit_intercept=True, lambda_1=1e-06, lambda_2=1e-06,  
n_iter=300, normalize=False, tol=0.001, verbose=False) 
basically, estimates the probabilistic model where the output 𝑦 is assumed to be Gaussian 
around 𝑀𝑀 is given by  
𝑝(𝑦|𝑀,𝑀,𝛼) = Ν(y|Mω,α) 
 
Where, 𝛼 is treated as a random variable that will be estimated from the data.  
 
The priors for 𝑀 is given by spherical Gaussian 
 
𝑝(𝑀|𝜆) = Ν(𝑀|0, 𝜆−1𝐈𝐩) 
 
Where 𝜆 is the estimated precision of the weights. 
 
Then, a univariate linear regression tests [284] (𝑓𝑟𝑞𝑔𝑟𝑞𝑠𝑠𝑖𝐿𝑞()) was used for testing the effect 
of a single regressor, sequentially for many regressors. It is performed by first calculating the 
correlation between each regressor (𝑖) and the target using  
 
��𝑀[: , 𝑖]–  𝑚𝑀𝑀𝑛(𝑀[: , 𝑖])� ∗  �𝑦 –  𝑚𝑀𝑀𝑛𝑦��
�𝑠𝑠𝑀(𝑀[: , 𝑖]) ∗  𝑠𝑠𝑀(𝑦)�  
 
It is frst converted to a 𝐹score and then to a p-value. 
 
A random forest regressor (RF) [168, 169] given by 
RandomForestRegressor(n_estimators=10, criterion=’mse’, max_depth=None, 
min_samples_split=2, min_samples_leaf=1, min_weight_fraction_leaf=0.0, 
max_features=’auto’, max_leaf_nodes=None,min_impurity_decrease=0.0, 
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min_impurity_split=None, bootstrap=True, oob_score=False, n_jobs=1, 
random_state=None, verbose=0, warm_start=False) 
results in the meta estimator that fits many sub classification decision trees. The classifier 
uses the average of probabilities predicted by each sub decision trees to get the final 
classification for each class. 
 
Then, LassoLarsCV [285], a cross-validated Lasso, using the LARS algorithm given by 
LassoLars(alpha=1.0, fit_intercept=True, verbose=False, normalize=True, 
precompute=’auto’, max_iter=500, eps=2.220446049250313e-16, copy_X=True, 
fit_path=True, positive=False) 
The optimization objective function to minimize is: 
 min 
𝜔
12𝑛𝑠𝑞𝑚𝑠𝑞𝑞𝑠 ‖𝑀𝑀 − 𝑦‖22 + 𝛼‖𝑀‖1  
 
Where, 𝛼 is the regularization strength, 𝑦 is the output variable and 𝑀 are the coefficients of 
the linear model. The lasso estimate thus solves the minimization of the least-squares 
penalty with 𝛼‖𝑀‖1 added, where 𝛼 is a constant and ‖𝑀‖1is the 𝑙1norm of the parameter 
vector. 
 
In the end, mean rank is calculated by averaging the scores from each algorithm and 
features with mean rank lower than 0.30 are filtered out.  
8.5.2 Multivariate analysis of covariance 
We also filtered out miRNAs and piRNAs that were confounded by age and gender by 
applying multivariate analysis of covariance (MANCOVA) [286, 287] on the reliable features 
with significant values less than 0.05. 
8.5.3 Model selection and performance  
The performance of selected features is then evaluated in an independent test cohort. The 
average Error and average number of trees parameter were calculated using a 10 fold cross 
validation on CV data which was obtained from the training data.    
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Figure 8.5-3 Optimal model selection and performance evaluation 
 
The random forest model implemented in R (v 3.2.2) with the package randomforest (v 
4.6.14) is trained with stratified sampling and class weights of 0.5 and 1.0 were used for the 
control class and the Alzheimer’s disease class to minimize the false negatives. Prediction 
on the training and test data is performed using the predict function from randomforest and 
roc function is used to get the test performance from the untouched test cohort data. The 
AUC values are plotted using the pROC [288] package with 500 stratified bootstrap [289] 
iterations to provide the confidence interval computed with Delong’s method [290] for the 
AUC values.  Smoothing of the AUROC curve was performed by calculating the 𝛼 and 𝛽 
coefficients of a linear regression line of the smoothed curve which is given by 
 
𝜙−1(𝑆𝐸) = 𝛼 + 𝛽𝜙−1(𝑆𝑆) 
 
Where, 𝜙is the normal quantile function value of sensitivities (SE) and specificities (SP). 
The variable importance is calculated from the importance function in randomforest package. 
The total decrease in node impurities is measured by taking the average node impurities on 
every split of the variable for all the trees generated in the random forest model. This node 
impurity is measured by Gini index (𝐼𝐺) which is given by 
 
𝐼𝐺(𝑝) = 1 − Σ𝑖=1𝐶 𝑝𝑖2 
 
Where, 𝐶 is the number of classes in the total samples set with 𝑖 ∈ {1,2, … ,𝐶}, and 𝑝𝑖are the 
number of samples that belong to the particular class 𝑖 in the total sample set. The Gini 
index for each variable is obtained and a Barplot of decreasing variable importance is 
plotted.  
 Materials and methods  74 
8.6 Handling of mice and nuclei preparation 
8.6.1 Ordering and upkeep of mice 
All mice used in the pilot experiment were adult male mice bought from JANVIER LABS. 
These wild type (WT) C57B16/J mice were pathogen free and were housed in the standard 
conditions with ad libitum access to food and water. The animal husbandry facility is located 
in  the basement of the European Neuroscience Institute (ENI), Göttingen that follows and 
ensure ethical experimental practices in accordance with animal protection laws and were 
approved by the Veterinary Institute in Oldenburg.  
8.6.2 Tissue collection 
Animals were sacrificed by cervical dislocation and the whole brain was isolated in ice-cold 
Dulbecco’s Phosphate Buffered Salt (DPBS, PAN-biotech GmbH) supplemented with EDTA-
free protease inhibitor cocktail (Roche). The CA1 and ACC regions were isolated, snap 
frozen in liquid nitrogen, and stored at −80 °C. 
8.6.3 Nuclei isolation and sorting 
In order to look at the interactions from neuronal and non-neuronal population of the cells for 
CA1 region, fluorescence-activated cell sorting (FACS) is used to sort the isolated nuclei. 10 
mice were pooled in each group to extract a sufficient amount of chromatin. Frozen mouse 
tissue from 10 mice was homogenized with the help of a micro pestle in low sucrose buffer 
(0.32 M Sucrose, 10 mM HEPES pH 8.0, 5mM CaCl2, 3 mM Mg(CH3COO)2, 0.1 mM EDTA, 
1% Triton X-100) and crosslinked with 1% formaldehyde (Sigma-Aldrich) for 5min at room 
temperature. The reaction was quenched by incubating for 5 min with 125mM glycine. The 
nuclei were centrifuged and re-suspended in 3ml of low sucrose buffer with protease 
inhibitors (Roche Complete) using. Nuclei were further homogenized mechanical 
homogenizer (IKA T 10 basic Ultra-Turrax) for half a minute.  The nuclei were purified 
through a sucrose cushion (10mM HEPES pH 8.0, 1M sucrose, 3 mM Mg(CH3COO)2, 1mM 
DTT) by centrifugation (3,200 rcf for 10 min in Oak Ridge centrifuge tubes).  6ml of cushion 
was used per 1.5 ml of lysate. The nuclear pellet was re-suspended in PBS, and aggregated 
were cleared by filtering through 70µm filter. The nuclei were stained with anti-NeuN 
Antibody, clone A60 (Trade name: Chemicon and catalogue number MAB377) diluted 1:500 
in PBS-T (0.1% Tween 20 in PBS) with 5% BSA and 3% goat serum, incubated for 30 min at 
4°C. The nuclei were washed 4 times with PBD-T and stained for 15min with anti-mouse 
Alexa 488 (Life Technologies) diluted 1:1000. The nuclei were washed once with PBS-T and 
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re-suspended in PBS-T with 5% BSA. Nuclei sorting was performed using the FACS 
machine (BD FACSARIA III) which is a 13 color 15 parameter high speed digital benchtop 
cell sorter with four excitation lasers that are adjustable. 
8.7 Chromosome Conformation Capture Sequencing (3C-Seq) 
8.7.1 Preparation of 3C library 
The sorted nuclei (NeuNpos and NeuNneg) from CA1 were then crosslinked with 
formaldehyde (1% final concentration) at room temperature (25°C approximately) for 10 
mins. The crosslinking reaction was stopped by adding glycine (final concentration 125mM). 
The crosslinked nuclei were pelleted down and washed with 1X PBS. The crosslinked nuclei 
were then again pelleted, frozen in dry ice and stored at -80°C.  
 
For the 3C library preparation, both samples were processed in parallel under similar 
experimental conditions. Briefly, the crosslinked nuclei were resuspended in 200 µL of 
NEBuffer DpnII (50 mM Bis-Tris-HCl, 100 mM NaCl, 10 mM MgCl2, 1 mM DTT (pH 6 at 
25°C)). The chromatin was then solubilized by adding SDS (0.1% final concentration) and 
incubating at 65°C for exactly 10 min. The SDS is quenched by Triton X-100 with 1% final 
concentration. The chromatin was next digested with 600 units of DpnII (NEB) restriction 
enzyme and incubated overnight at 37°C in a thermomixer (Eppendorf). DpnII was heat 
inactivated the following morning by incubating the digestion mixture at 65°C for 30 minutes. 
A ligation mixture (cocktail mix in Table 8-2 The ligation master mix) was prepared 
containing 30U of T4 DNA ligase (Invitrogen) to the samples and incubated for 4 hours at 
16°C.  The ligated samples were reverse crosslinked by adding 600 µg of Proteinase K and 
incubating them at 65°C overnight. DNA was purified using standard phenol-chloroform 
extraction followed by DNA precipitation using sodium acetate pH 5.2 (to a final 
concentration of 0.3M) and 2.5 volume of ice-cold absolute ethanol. The mixture was 
incubated at minus 80°C for 1 hour and then centrifuged at 12000 x g for 20 minutes at 4°C. 
The pellet was then resuspended in TE buffer and passed through Amicon-Ultra 30K column 
(0.5 mL) and washed with TE buffer pH 8 for 3 times. The washed DNA which contains the 
3C library was collected by inverting the column on a fresh collection tube place by spinning 
at 1000 x g for 2 minutes. The NeuN-3C library was then subjected to 3C QC step. 
Table 8-2 The ligation master mix 
 1 reaction (µl) per 15ml tube 
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8.7.2 Quantification of 3C library 
Successful preparation of 3C library was validated using 3C qPCR with standard conditions. 
Due to the very low yield of 3C library, QC of only one sample (NeuNneg) could be 
performed. 3C primers were designed (Table 8-3) on a gene desert region of the mouse 
genome (mm9) in Chr 5 near the DpnII cut site to probe for a short range interaction. The 
qPCR analysis showed the positive amplification curve (Fig 7.3.2). The qPCR product was 
run on an EtBr stained 2% agarose gel. A DNA band of 384 bp was detected which conform 
to the expected amplicon size showing the successful preparation of the NeuN-3C library. 
One pair of primers (primer 25 and 26) probing an interaction 4.1 kb apart were used for 3C 
qPCR using 3µL of NeuN-3C library with expected Amplicon size 384 bp. The location of the 
primers and restriction enzymes around the primers and between them are shown in Figure 
8.7-1. 
 
Table 8-3 3C primers details 
# 













25 Mouse_MMC9_DpnII_Fwd1 133376673 133376693 CAGGACCTGATTGCTAAACTG 53.4 47.6 21 
26 Mouse_MMC9_DpnII_Rev1 133384528 133384549 TGTATACCCGCACACAATGAAT 54.5 40.9 22 
 
 
10X ligation buffer 447 
10mg/ml BSA 48 
100mM ATP 48 
Water 4023 
T4 DNA ligase  
(ligase separately added into individual tubes) 
30 
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Figure 8.7-1 Genomic location of primers and restriction enzymes 
 
After the primer design and checking for an interaction, 3C reactions were performed. 3 µL 
of the NeuN-3C DpnII library were used per reaction (Table 8-4) 
Table 8-4 Reaction usage 
 
Then PCR amplification was performed using the parameters (Table 8-5). The fluorescence 
signal measured in relative fluorescence units (RFU) and the number of PCR cycles are 
plotted in a PCR amplification curve (Figure 8.7-2). The background fluorescence was 
plotted as green line. 
Table 8-5 PCR tubes 
 Components 1X (µl) 
1 KAPA SYBR mix (2X) 10.0 
2 Forward 3C primer (10uM) 1.0 
3 Reverse 3C primer (10uM) 1.0 
4 Template (3C library) 3.0 
5 DNAse and RNAse free water 5.0 
 Total volume (per reaction) 20.0 
# Step Temperature (°C) Time Number of cycle(s) 
1 Initial denaturation 98 3 mins 1 
2 Denaturation 98 15 seconds 1 
3 Annealing and Elongation 60 30 seconds 54 
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Figure 8.7-2 PCR amplification curve 
Table 8-6 Standard curve range 
Well Fluor Target Sample name Cq 
C03 SYBR 25-26 (nearby) 250516 NeuNneg DpnII-3C library (0.6ng) 41.63 
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Figure 8.7-3 Melting curve and 3C interaction on a gel 
The Cq value of the standard curve is calculated and shown in Table 8-6 
The melt curve analysis program (Figure 8.7-3): 
• 65°C for 5 seconds 
• 95°C for 0.5°C/cycle 
• 12°C for ∞ 
The negative rate of change of fluorescence units compared to the temperature (°C) is 
plotted in Figure 8.7-3 A showing a single peak. The qPCR product was run on a 2% 
agarose gel for the confirmation of the short range interaction (3C product) of the expected 
size from the 3C library from Figure 8.7-3 B. 
8.8 Sequencing of 3C-seq library 
8.8.1 Preparation of 3C library 
The sorted nuclei were first homogenized by Dounce homogenizer to lyse almost all cells. 
The quality of homogenization was checked under the microscope. It is then crosslinked with 
1% formaldehyde at room temperature (25°C approximately) for 10 mins. The crosslinked 
chromatin was digested with DpnII (GATC) restriction enzyme overnight at 37°C. DpnII was 
inactivated the next morning and a ligation mixture was added and samples were kept for 5 
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overnight to reverse crosslink the ligated samples. DNA was precipitated and washed 
thoroughly.  
8.8.2 Quantification of 3C library and library preparation 
Short and long looping interactions were quantified using PCR with standard conditions (50 
cycles). Due to the very low yield of genomic DNA, only one QC of (NeuN minus) could be 
performed. Small distance primers were designed at the DpnII site to check for short range 
interactions. The PCR product was run on 2% agarose gel with the water control and the 
band intensities were quantified with the standard imaging software.  The titration curve of 
PCR product vs. input DNA should be plateaued for a successful 3C library preparation. The 
library preparation was performed with NEBNext® Ultra DNA Library Prep Kit for Illumina 
(cat. no. E7370L). For PCR primers primer with index 2 for samples 3C CA1 pos and index 4 
for 3C CA1neg was used. Finally, the sequencing was performed on Illumina HiSeq2500.  
8.9 Processing of 3C-seq sequencing data 
8.9.1 Generation of raw fastQ files and quality control 
The generation and quality control of the raw fastQ files for the 3C-seq sequencing data is 
performed in the same way as mentioned in the section 8.2.1 above for the generation of 
raw fastQ files and section 8.2.2 above for the quality control reporting of the raw fastQ files. 
The quality control statistics were presented in Table 9-5, Figure 9.6-1 and Figure 9.6-2. 
Additional file conversions and quality controls are described in the subsequent sections with 
the subsequent analysis.  
8.9.2 Iterative mapping to the reference genome 
The 3C-seq paired end data is unique in the sense that the paired end mode cannot be used 
even when the reads are paired end as they do belong to the same fragment. The two ends 
of the read are in-fact comes from two different genomic locations. In order to optimize the 
mapping, they are mapped like single end reads and later the information is combined to get 
the chromatin looping interaction. Another, important point about the 3C-seq data is that the 
DNA fragments that goes into the sequencing contain a restriction enzyme junction. With the 
four-base cutter DpnII, an average fragment size is around 300-500 bp. The fragments are 
then sequenced with PE 2x150 bp paired end sequencing. With these parameters, around a 
quarter of the reads contains a restriction enzyme junction as only a part of the fragment is 
sequenced.   
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The mapping is performed iteratively starting with the first 25 bp of the reads from the 5’ end 
are mapped to the mouse reference genome. The assembly of the mouse genome (mm9, 
NCBI Build 37 in July 2007) as well as repeat annotations and GenBank sequences were 
downloaded from http://hgdownload.soe.ucsc.edu/goldenPath/mm9/bigZips and random 
contigs were filtered out using Unix command grep [259].  
 
The mapping for each read pair is individually performed using bowtie (v 1.1.2) [256] with 
fine-tuned parameters for optimal mapping. The first iteration is conservative in nature, 
allowing no mismatches during the mapping of the roads. The parameters are:   
• -v 0 is used is set for end-to-end hits with zero mismatches to keep 
the mapping very conservative for this iteration 
• -p/--threads 8 are the number of alignment threads for faster mapping 
• -S/--sam is set for writing all the mapped reads into the Sequence 
Alignment Map (SAM) format 
• -a/--all is set to get all alignments for every read 
• -m 1 is set to remove all alignments that have more than one 
reportable alignment 
• --un <unmapped_fastq> to save all the unmapped reads for next 
iteration where these reads will be mapped again but with a longer 
read length 
 
The resulting SAM files are converted to BAM (Binary SAM) files using samtools (v 1.3.1) 
[262] with the command: 
samtools view -S -b input.sam > output.bam 
 
The resulting BAM file is indexed using the command: 
samtools index output.bam 
 
In the next and all subsequent iterations until the read length is reached or all the reads are 
mapped uniquely, the reads are trimmed with 5 bp longer than the previous iteration and 
mapped with one mismatch using bowtie (v 1.1.2) with same parameters except  
• -v 1 is used is set for end-to-end hits with one possible mismatch 
for a little relaxed mapping strategy 
 
The individual mapped BAM files from every iteration was combined into one BAM file and 
indexed using samtools. All the unmapped reads were discarded in this case. All the 
mapping iterations were performed on the GWDG’s high performance computing cluster 
(HPCC) [254] using gwdu103.gwdg.de as the master node. The jobs were launched on to 
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“fat” queue with a maximum of 16 cores, a maximum time constraint of 48 hours and 
maximum memory constraint of 32GB.   
8.9.3 Reads assignment to restriction enzyme fragments and filtering 
The list of restriction enzyme fragment is created by assigning all the fragments that are 
separated by the restriction enzyme DpnII (GATC) which is a four-base cutter. For DpnII, 
there will be approximately 6 million restriction enzyme fragments. After the mapping is 
finished, the reads are also assigned to these genomic restriction enzyme fragments. This is 
important as it will be used to filter out the various 3C-seq library preparation and 
sequencing related artifacts are shown in Figure 8.9-1. Following the assignment of all the 
mapped reads to the restriction enzyme fragments, all the reads that do not fall into the 
unique valid pairs are filtered out and only the unique valid pairs are considered for the 
downstream analysis. The results of the mapping and all the artifacts are presented in Table 
9-7.  
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Figure 8.9-1 3C-seq mapping artifacts (Adapted from Fides Lay’s HiC workshop [291]) 
8.9.4 Assign reads to genomic bins and perform iterative correction 
After the identification of the unique valid pairs, the reads are binned to a particular 
resolution for further analysis. As mentioned in the previous section, there are approximately 
6 million genomic fragments identified by 3C-seq. This makes approximately 36 trillion 
possible pairwise interactions. Even with the advanced next generation sequencing, working 
with the fragment level resolution requires a very high depth of sequencing, which need a 
high amount of input material and can be very expensive. Due to the lack of enough reads, a 
lot of fragments and their corresponding pairwise looping interaction cannot be identified. To 
get an abstract idea, instead of working with fragment level resolution, the data were binned 
to a certain resolution, for example 1 MB bins or 500 KB bins [236]. This will also level out 
outliers and reduce noise. All the restriction fragments whose center falls into the bin is 
assigned to the bin. The 3C-seq neuronal and non-neuronal data are binned to 100 kb, 200 
kb, 500 kb, and 1 Mb sized bins. Due to an insufficient number of unique valid pairs, 100 kb 
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bins and 200 kb bins do not provide enough information to call topologically associating 
domains or get any conclusion from the binned data. In this pilot study, 500 KB and 1 MB 
data are used. After binning is performed, low quality bins that do not convey any information 
are filtered out (marked as NANs) and not be used in further downstream calculations. After 
the filtering at the bin level, Iterative correction of the matrix is performed. This removes 
various known bias like variable length of fragments and GC content [292, 293] and 
unknown bias [294]. The iterative correction and normalization is performed by applying 
Sinkhorn–Knopp balancing algorithm [295] to the binned data [296, 297]. The normalized 
matrix Ψ𝑞𝐿𝑟𝑚𝑞𝑞𝑖𝑛𝑞𝑚 being doubled stochastic with both the sum of rows and column being 1 is 
given by 
 
Ψ𝑞𝐿𝑟𝑚𝑞𝑞𝑖𝑛𝑞𝑚𝑖,𝑗 = Ψ𝑟𝑞𝑟Ψ𝑚𝑖𝑞𝑔𝐿𝑞𝑞𝑞𝑖,𝑖Ψ𝑚𝑖𝑞𝑔𝐿𝑞𝑞𝑞𝑗,𝑗 
 
Where, Ψ𝑟𝑞𝑟 is the initial raw count matrix binned at a particular resolution (1 Mb or 500 kb), 
Ψ𝑚𝑖𝑞𝑔𝐿𝑞𝑞𝑞 is the bias matrix and 𝑖, 𝑗 are the bins of the matrix. These matrices are all 
symmetric matrix and can be visualized as square heatmaps (Figure 9.7-1) or triangular 
heatmaps (Figure 9.7-5). 
8.9.5 Defining topological regions and domains 
Within the various levels of chromatin organization, at a certain level of abstractions lies the 
few 100s KB structures that have a specific looping interaction profile. These domains are 
called topologically associating domains or TADs [209, 210, 292] (6.7.1.3 above). Both the 
insulation score [298] and directionality index [209] methods are used to identify TADs for 
the matrices binned at 500 kb resolution.  
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Figure 8.9-2 Schematic to identify topologically associating domains (TADs) by two 
competing methods 
 
TADs used in the study for the neuronal and non-neuronal populations are called with 
insulation delta span which is the insulation delta window of size 2 Mb and insulation square 
of size 1.5 Mb for the 500 kb resolution TADs identification.  
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9.   Results 
9.1 CSF exosomes and small non-coding-RNAome 
9.1.1 Analysis of isolated RNA from CSF exosomes and exosomal free 
CSF fraction 
We started the analysis with the aim to confirm that small non-coding RNAs are enriched 
within CSF exosomes. To this end, we obtained CSF from 36 individuals and isolated 
exosomes, which were confirmed via immunoblot analysis of the marker proteins Flotilin-2 
and CD-63, electron microscopy and via analysis of particle size (Figure 9.1-1 A, B, C). Next, 
we analyzed isolated RNA from these exosomes and from the exosomal free CSF fraction 
via a bioanalyzer microfluidics device. The corresponding electropherogramms show that a 
significant amount of RNA with a particularly high peak of a small RNA species is detectable 
in the exosomal CSF fraction. In contrast, comparatively little RNA was obtained from 
exosomal free CSF. Treating RNA samples obtained from CSF exosomes with DNAase did 
not affect RNA integrity while treatment with RNAase eliminated the small RNA peak (Figure 
9.1-1 D, E, F, G). This data confirms that the human CSF contains exosomes that carry 
small RNAs. 
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Figure 9.1-1 Profile of exosomal RNA from human CSF A. Exosomes isolated from human 
CSF was analyzed via EM. B. Fragment size using a nanosight instrument and via 
immunoblot for exosomal marker proteins. C. Electropherogram showing the profile of RNA 
isolated from exosomes. D. Electropherogram showing the profile of RNA isolated from 
exosome free CSF. E. Electropherogram showing the profile of RNA isolated from exosomes 
treated with DNAase (F) and RNAase (G). 
9.1.2 miRNAs and piRNAs in CSF exosome small non-coding-
RNAome 
The advent of the next generation sequencing (NGS) technologies and the decreasing cost 
of sequencing, enabled the scientific community to study small RNAs in detail. Analysis of 
small RNAs is challenging due to the short and repeatable sequences. There are many tools 
to analysis small RNA data [299]. However, there were many shortcomings associated with 
these existing tools and to get a global and complete picture of the small RNAs I developed 
the small RNA mapping and analysis pipeline: GJSrMap 
(https://github.com/gauravj49/gjsrmap). The pipeline is available as a standalone installation 
(cloned from github) or through the webtool which will be accessible in the future from the 
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webpage (http://www.fischerlab.uni-goettingen.de/tools/gjsrmap). Details and inner working 
of the pipeline is mentioned in the methods and material section 8.3 above. 
We analyzed the small RNA content of CSF exosomes obtained from two independent 
cohorts of Alzheimer’s disease patients and individuals that did not suffer from any 
neurodegenerative disorder and performed small RNA-sequencing according to DZNE 
RNAome database SOPs using Illumina reagents on an in-house Illumina HiSeq 2000. All 
the analysis of the data is performed in-house. Majority of CSF smallRNAs are miRNAs and 
piRNAs (Figure 9.1-2 A).  Amongst the 5 highest expressed miRNAs in CSF exosomes were 
miR-10a-5p, miR-22-3p and mIR-204-5p that have been previously linked to memory 
function and/or neurological diseases [300-304]. Recent studies also show the role of 
piRNAs in neurological diseases like Alzheimer's disease [122] and cancer [305]. The 5 top 
expressed piRNAs showed comparable expression levels to miRNAs (Figure 9.1-2 B).  
Compared to the genomic piRNAome, the CSF piRNAome has a completely different profile. 
A majority of genomic piRNAs are coming from distal intergenic regions and only a fraction 
comes from 1st exon. On the other hand, the majority of piRNAs in the CSF pen-name 
comes from 1st exon and a small fraction come from the distal intergenic regions (Figure 
9.1-2 A). This is quite interesting as a recent study [306] shown that the small non-coding 
RNAs derived from the first exons of protein coding genes are better at distinguishing 
between patients compared to healthy individuals. This suggests that piRNAs may have a 
potential role in classifying and predicting the disease pathology. 
 
 
Figure 9.1-2 miRNAome and piRNAome in CSF exosomes  
A. Pie chart (Left) representing small non coding RNAs in human CSF exosomes. Here 
miRNAs and piRNAs make up almost entire small non coding RNAome. Pie chart (top right) 
showing genomic annotation of human piRNAome. Here, the majority of piRNAs lies in the 
distal intergenic region. Pie chart (bottom right) shows genomic annotation of expressed 
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piRNAome in the human CSF exosomes. Here, the majority of piRNAs lies in the 1st exon of 
genes.  B. Top 5 expressed miRNAs (Blue) and piRNAs (Red) in human CSF exosomes. 
Here y-axis represents the mean normalized expression and x-axis represents 
miRNAs\piRNAs. 
9.1.3 miRNAs arm expression in CSF exosomes and brain tissues 
Mature microRNAs are derived from both 5’ and 3’ ends of their pre-microRNAs which are 
known as 5-p and 3-p arms. The 5-p and the 3-p arm of a given miRNA are often expressed 
at different levels. We need to quantify the expression of both arms to define if the 5-p, 3-p 
or both arms of a given miRNA are biologically active since the precise biological function of 
many miRNAs are still unclear. The highest expressed arm is often considered to be the 
active one. It was previously suggested that the inactive arm of a given microRNA is sorted 
into exosomes as a cellular clearance mechanism, while at the same time there is evidence 
that transport of molecules from one cell to another via exosomes serves important 
biological functions. 
 
Figure 9.1-3 Heat map showing expression values of the 3-p and 5-p arms of all miRNAs 
detected in human CSF and in the human cortex (Brodmann Area 9)  
Thus, we performed small RNA-sequencing from postmortem human prefrontal cortex 
(Brodmann area 9) and compared the expression pattern of the 5-p and 3-p arms for all 
miRNAs detected in CSF to the corresponding expression pattern observed in the human 
brain. The pattern of the 3-p vs. 5-p arms of microRNAs detected in CSF was similar to the 
pattern observed in postmortem human brain tissue and confirmed that for the majority of 
the miRNAs only one arm was highly expressed (Figure 9.1-3). This finding supports the 
view that the small non-coding-RNA content of CSF exosomes – at least in part – resembles 
the small non-coding-RNA content of the parent cells. The data have to be interpreted with 
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care, since the parental cell for CSF detected exosomes is not precisely known and likely 
includes not only various brain regions but also other cells [307]. 
9.1.4 Cellular small non-coding-RNAome and exosomal small non-
coding-RNAome 
After looking into the expression of mature microRNA arms and profiling the small non-
coding-RNAome in exosome, the follow-up analysis is to study the relationship between 
cellular small non-coding-RNAome and exosomal small non-coding-RNAome which may 
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Figure 9.1-4 Pearson correlation between miRNA and piRNA expression values of 
hippocampal and cortical neurons against the miRNA and piRNA expression in the 
exosomes released from these cells. Here x-axis represents the normalized expression of 
exosomal small RNA and the y-axis represents the normalized expression of cellular small 
RNA. The Pearson correlation coefficient and significance level are mentioned in the plot. 
 
To address the questions if the small non-coding-RNA content of exosomes released from 
neurons allows making conclusions about the corresponding cellular small non-coding-
RNAome, we decided to test the correlation of miRNA and piRNA expression in primary 
cortical and hippocampal neurons and in their corresponding exosomes. Exosomes were 
isolated from the media supernatant of the corresponding cells. Subsequently the exosomal 
and the cellular RNA was prepared and subjected to smallRNA sequencing. For both, 
miRNAs and piRNAs, we detected a highly significant correlation between cellular and 
exosomal fractions (Figure 9.1-4). 
9.2 A CSF miRNAs/piRNAs signature to diagnose Alzheimer’s 
disease patients along with the available clinical markers 
9.2.1 Demographic information for the samples included in the 
biomarker signature analysis 
The study was performed on two independent cohorts of Alzheimer’s disease patients and 
controls. Cohort 1 consisted of 23 Alzheimer’s disease patients and 38 control individuals 
after removing outliers and age-matched control individuals that did not suffer from any 
neurodegenerative disorder (Table 9-1).  
Table 9-1 showing demographic information for the samples included in the biomarker 
signature analysis. Abbreviations: AD, Alzheimer’s disease; F, female; M, male. 
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Samples were collected at the University Medical Center Göttingen (Germany) between Jan 
2012 and Mar 2013. Cohort 2 consisted of 19 Alzheimer’s disease cases and 44 control 
individuals after removing outliers and age-matched control individuals from which CSF 
samples were collected at the University Medical Center’s in Göttingen, Tübingen, and 
Kassel (Germany) between Apr 2013 and Oct 2014. 
9.2.2 Performance of clinical signatures on replication cohort 
The hallmarks of the Alzheimer’s disease are the presence of Amyloid-β plaques and tau 
tangles in the brain. The traditional CSF clinical biomarkers to identify Alzheimer’s disease 
correspond to Aβ1-42, total-Tau (tau) and phospho-Tau (pTAU) [308]. Various studies [309-
315] have shown that Alzheimer’s disease patients have higher levels of pTAU (Figure 9.2-1 
A).  
 
Figure 9.2-1 showing summary statistics about the clinical markers used in the study. 
Abbreviations: Alzheimer’s disease, Alzheimer’s disease; Aβ40 and Aβ42, amyloid beta 
peptide 40 and 42 amino acids; pTAU is phosphorylated TAU. B. Receiver operating 
characteristic (ROC) plot was obtained during the performance testing of the clinical markers 
on replication cohort 2 with mean test AUC of 0.87. The training was done on cohort 1 with a 
tenfold cross validation. An inset plot showing the variable importance which explains how 
good a variable in classifying the data. Here x-axis represents the mean decrease in Gini 
and the y-axis shows each variable which are ordered top-to-bottom as most- to least-
important. In this case, pTAU is most informative. 
A random forest machine learning classification approach with a 10 fold cross-validation 
protocol was used to assess the combined performance of both clinical markers (pTAU and 
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Aβ42/40 ratio). Clinical marker pTAU was found to be more informative than the Aβ42/40 
ratio (Inset plot Figure 9.2-1 B). The performance of this model was then tested on cohort 2 
which allowed us to distinguish Alzheimer’s disease patients from controls with an AUC of 
0.87 (Figure 9.2-1 B).  
9.2.3 Identification of small non-coding RNAs signature 
Small RNA sequencing data obtained from cohort 1 was used to perform an iterative feature 
selection protocol (section 8.5.1 above and section 8.5.2 above). Data filtering and 
normalization of the data (section 8.4 above) was performed first given the small number of 
samples and a large number of miRNAs and piRNAs in the data. The measure of relevance 
procedure [275] was then used to trim down the number of miRNAs and piRNAs and to keep 
the informative variables (Figure 9.2-2).  
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Figure 9.2-2 Identification and quantification of small non-coding RNAs signature  
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A. Showing the Measure of Relevance (MoR) for miRNAs (left) and piRNAs (right) signature 
for identifying differences between Alzheimer’s disease and control samples in cohort 1. The 
dotted red line represents critical more value. The miRNAs and piRNAs that are above 
dotted red line are considered informative. miRNAs marked in blue and piRNAs marked in 
red are part of the final signature. Inset showing fold change (log) of most informative 
signature and their significance level (p-value <= 0.1) with Significance codes: 0 ‘***’ 0.001 
‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 after performing MANCOVA by age and gender as confounding 
factors. B Barplots showing the expression of the putative signature in training cohort 1 and 
replication cohort 2. The expression of control samples was scaled to one and the 
expression of Alzheimer’s disease samples were scaled appropriately. Dark color shows 
control samples and light shade of the same color represents the Alzheimer’s disease 
samples. Here, the signature follows the same trend in both training and replication cohort. 
Five signatures are upregulated in Alzheimer’s disease compared to controls while one 
signature is downregulated. 
  
In addition, a reliability test [276] was performed to ensure the effectiveness of the 
informative variables that can discriminate between the samples reliably. MiRNAs and 
piRNAs that were detected in both of the above mentioned approaches and were not 
affected by age or gender were considered as the candidate signature for further analysis. 
The set of ‘informative and ’‘relevant’ miRNAs and piRNAs was further reduced after filtering 
out low ranking miRNAs and piRNAs measured using machine learning feature selection 
methods (Figure 9.2-2 C). In the end, three miRNAs, namely hsa-miR-27a-3p, hsa-miR-30a-
5p, miR-34c-3p and three piRNAs, namely hsa-piR-019949, hsa-piR-020364 and hsa-piR-
019324 were identified and treated as potential small non-coding RNAs signature.  
9.2.4 The role of clinical and small non-coding RNA signatures 
At present clinical markers are used extensively in hospitals and clinics for the diagnosis of 
Alzheimer’s disease. These clinical markers have been shown to have a high sensitivity 
rates (95%) but poor specificity rates (36%) [311]. Nonetheless, these clinical biomarkers are 
now used as a common diagnostic tool for the diagnosis of Alzheimer’s disease [316]. 
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Figure 9.2-3 Heatmaps showing Pearson correlation coefficient between the normalized 
expression of putative biomarker signature and levels of clinical markers in cohort 1 (top) 
and in the replication cohort 2 (bottom). The Pearson correlation coefficients and a two-
sample paired t-test were calculated and the significance is marked as (*) with p-value < 
0.05. 
Due to the complex pathologies of neurodegenerative diseases and the fact that multiple 
clinical phenotypes can be linked to just one disease pathology and vice versa, it is 
important to know whether the same information and resulting diagnosis is provided by the 
clinical markers and small non-coding RNA signatures or they cover different aspects of 
disease pathology and whether the combination of both can provide a clearer picture. For 
this, a correlation analysis of clinical and small non-coding RNA signatures is performed. 
Almost all clinical and small non-coding RNA signatures are not correlated (Figure 9.2-3).  
9.2.5 The performance of small non-coding RNAs signatures on 
replication cohort 
The performance of the small non-coding RNAs signatures was performed in three different 
stages. First, the performance of only miRNAs signature was performed using a random 
forest machine learning classification approach with a 10 fold cross-validation protocol. The 
miRNAs alone signature performed very close to a random classifier with the poor AUC of 
0.56 (A). The most informative feature was hsa-miR-30a-5p (Figure 9.2-4 A inset). In 
comparison to miRNAs, little is known about the role of piRNAs that were however, 
expressed at similar levels in the CSF exosomes (Figure 9.2-2 C). The performance of  
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piRNAs signature was far better in comparison to the miRNAs and were able to distinguish 
Alzheimer’s disease patients from controls with an AUC of 0.82 (Figure 9.2-4 B). The most 
informative feature was hsa_piR_019949 (Figure 9.2-4 B inset). The performance of 
combined miRNAs and piRNAs signature provides a slight improvement on the diagnosis 
and were able to distinguish Alzheimer’s disease patients from controls with an AUC of 0.83 
(Figure 9.2-4 C).  The top two most informative features were hsa_piR_019949 and hsa-
miR30a-5p (Figure 9.2-4 C inset).  
 
Figure 9.2-4 Performance of signature on replication cohort. A. ROCs showing the 
performance of miRNA signature on separate replication cohort (cohort 2). The training was 
done on cohort 1 with tenfold cross validation. Mean AUC of 0.56. Barplot (right) shows the 
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variable importance explaining how good a variable is in classifying the data. Here x-axis 
represents the mean decrease in Gini and the y-axis shows each variable which are ordered 
top-to-bottom as most to least important. In this case, hsa-miR-30a-5p is most informative. 
B. ROCs showing the performance of piRNA signature on separate replication cohort (cohort 
2). Mean AUC of 0.82 was obtained. Barplot (right) show the variable importance explaining 
how good a variable is in classifying the data. Here x-axis represents mean decrease Gini 
value and the y-axis shows each variable which are ordered top-to-bottom as most- to least-
important. In this case, hsa_piR_019949 is most informative. C. ROCs showing the 
performance of combined miRNA and piRNA signature on separate replication cohort 
(cohort 2). Interestingly the mean AUC of 0.83 was obtained suggest that the combined 
signature performed way better than the miRNA signature and marginally better than the 
piRNA signature. An inset plot showing the variable importance which explains how good a 
variable in classifying the data. Here x-axis represents the mean decrease in Gini and the y-
axis shows each variable which are ordered top-to-bottom as most- to least-important. In this 
case, hsa_piR_019949 is most informative. D. ROCs showing the performance of combined 
clinical markers and smallRNA signature on separate replication cohort (cohort 2). The mean 
AUC of 0.98 was obtained showing that the combined signature performed massively better 
than the individual clinical markers or the smallRNAs signature. 
 
Apart from the similar performance, the miRNAs/piRNAs signature also does not correlate 
significantly with the Aβ and phospho-Tau levels (Figure 9.1-4) suggesting that the small 
non-coding RNAs signatures provide an additional layer of support to the current diagnosis 
of Alzheimer’s disease patients. In order to cover all the aspects that both clinical markers 
and smallRNAs signature provide, the performance of both clinical markers and smallRNA 
signature was evaluated and had a massive improvement in the diagnosis where they were 
able to distinguish Alzheimer’s disease patients from controls with an AUC of 0.98 (Figure 
9.2-4 D).  The top three most informative features were hsa_piR_019949, hsa-miR-30a-5p 
and Aβ42/40 ratio (Figure 9.2-4 D inset).  
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9.3 CSF smallRNAs signature along with the available clinical 
markers as a promising biomarker to predict the progression 
from mild cognitive impairment (mci) to Alzheimer’s disease  
9.3.1 Demographic information for the samples included in the 
biomarker signature analysis 
The prediction cohort used in this study is cohort 3 where the samples were collected 
Erlangen (Germany). Cohort 3 consisted of 17 individuals with MCI of which 10 years later, 6 
individuals had converted to Alzheimer’s disease (mciAD) while 11 did not develop 
Alzheimer’s disease (mciStable) (Table 9-2).  
Table 9-2 Showing demographic information for the samples included in the biomarker 
signature analysis. Abbreviations: mciAD, mild cognitive impairment patients that went on to 
develop Alzheimer’s disease; mciStable, mild cognitive impairment patients that did not 
develop Alzheimer’s disease; F, female; M, male. 
 
9.3.2 The role of small non-coding RNA signatures in predicting the 
onset of disease progression 
The expression profile of many smallRNAs signatures of the MCI individuals (Figure 9.3-1) 
does not follow the same direction for their respective counterparts showing there are some 
differences that are unique to MCI individuals.  
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Figure 9.3-1 A. Barplot (left) showing the expression of the putative signature in training 
cohort 1 and predictive replication cohort 3. The expression of mciStable samples was 
scaled to one and the expression of mciAD samples was scaled appropriately. Dark color 
shows control/mciStable samples and light shade of the same color represents the 
Alzheimer’s disease/mciAD samples. Three signatures are downregulated in mciAD 
compared to mciStable and remaining three signatures are unregulated.  
9.3.3 The performance of small non-coding RNAs signatures on 
predictive replication cohort 3 for the predicting the onset of 
disease progression 
Similar to disease diagnosis, the performance of the small non-coding RNAs signatures was 
performed in three different stages. First, the performance of only miRNAs signature was 
performed using a random forest machine learning classification approach with a 10 fold 
cross-validation protocol. The miRNAs alone signature performed very close to a random 
classifier with the AUC of 0.70 (Figure 9.3-2 A). The performance of combined miRNAs and 
piRNAs on the other hand performed poorly with an AUC of 0.62 (Figure 9.3-2 C). The 
performance of piRNAs signature is excellent with an AUC of 0.86 (Figure 9.3-2 B).   
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Figure 9.3-2 Performance of signature on predictive replication cohort 
A. ROCs (top left) showing the performance of miRNA signature on separate predictive 
replication cohort 3. Mean AUC of 0.70 was obtained suggesting decent predictive ability. B. 
ROCs showing the performance of only piRNA signature on separate predictive replication 
cohort 3. The training was done on cohort 1 with a tenfold cross validation. Mean AUC of 
0.86 suggesting excellent predictive ability. C. ROC shows the performance of combined 
miRNA and piRNA signature on separate predictive replication cohort 3. The mean AUC of 
0.0.62 was obtained suggesting a poor performance of smallRNAs signature. 
9.4 CSF smallRNAs signature in blood and brain 
9.4.1 Demographic information for the samples included in the 
biomarker signature analysis 
The samples from the blood plasma exosomes cohort (cohort 4) were collected in Göttingen 
(Germany). Cohort 4 consisted of 10 Alzheimer’s disease patients and 12 control individuals 
after removing outliers and age-matched control individuals that did not suffer from any 
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neurodegenerative disorder (Table 9-3). The samples for cohort 5 are the postmortem brain 
tissue samples from the Prefrontal Cortex region. These samples are taken from the 
published study [317]. The samples were collected and processed in Leuven, Belgium. 
Cohort 5 consisted of 6 Alzheimer’s disease and 6 control individuals.   
Table 9-3 showing demographic information for the samples included in the biomarker 
signature analysis. Abbreviations: PFC, Prefrontal Cortex; AD, Alzheimer’s disease; F, 
female; M, male 
 
9.4.2 Role of CSF exosomes small non-coding RNA signatures in 
blood and brain 
The expression profile of many CSF exosomes smallRNAs signature in the blood plasma 
exosomes and prefrontal cortex region of the brain. The entire smallRNAs signatures 
obtained from the CSF exosomes are expressed in the prefrontal cortex of the brain. 
However, few piRNAs were not expressed in the plasma exosomes (Figure 9.4-1). 
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Figure 9.4-1 Barplots showing the expression of the putative signature in training cohort1, 
plasma exosomes cohort 4 and PFC brain cohort 5. The expression of control samples was 
scaled to one and the expression of Alzheimer’s disease samples was scaled appropriately. 
Dark color shows control samples and light shade of the same color represents the 
Alzheimer’s disease samples. 
9.4.3 Performance of CSF exosomes small non-coding RNAs 
signatures in plasma exosomes blood samples (cohort 4) and 
from the post mortem brain tissue samples from the Prefrontal 
Cortex region (cohort 5) 
Similar to disease diagnosis, the performance of the small non-coding RNAs signatures was 
performed at three different stages. First, the performance of only miRNAs signature was 
performed using a random forest machine learning classification approach with a 10 fold 
cross-validation protocol. The miRNAs alone signature performed very well in classifying 
Alzheimer’s disease against the controls with an AUC of 0.84 (Figure 9.4-2 A) in cohort 4. 
The same miRNAs alone signature also performed well in cohort 5 with an AUC of 0.70 (Fig. 
Figure 9.4-2 D). Then the performance of piRNAs signature was assessed in both cohorts. 
The piRNAs only signature performance was not good at classifying Alzheimer’s disease 
against the controls with an AUC of 0.67 (Figure 9.4-2 B) in cohort 4. On the other hand, the 
same piRNAs alone signature performed extremely well in cohort 5 with an AUC of 0.97 
(Figure 9.4-2 E).         
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Figure 9.4-2 Performance of signature in blood and brain samples 
A. ROCs showing the performance of miRNA signature on plasma exosomes cohort 4. 
Mean AUC of 0.83 was obtained suggesting good classification ability. B. ROCs showing the 
performance of only piRNA signature on plasma exosomes cohort 4. The training was done 
on cohort 1 with a tenfold cross validation. Mean AUC of 0.67 suggesting some classification 
ability. C. ROCs shows the performance of combined miRNA and piRNA signature on 
plasma exosomes cohort 4. The mean AUC of 0.78 was obtained suggesting that the 
combined signature also has good classification ability on the blood data. D. ROCs showing 
the performance of miRNA signature on PFC brain cohort 5. Mean AUC of 0.70 was 
obtained suggesting classification ability. E. ROCs showing the performance of only piRNA 
signature on PFC brain cohort 5. The training was done on cohort 1 with a tenfold cross 
validation. Mean AUC of 0.97 suggesting extremely good classification ability. F. ROCs 
shows the performance of combined miRNA and piRNA signature on PFC brain cohort 5. 
The mean AUC of 0.89 was obtained suggesting that the combined signature has very good 
classification ability on the PFC brain data. 
The performance of combined miRNAs and piRNAs, on the other hand, performed well in 
the diagnosis of Alzheimer’s disease. Here the smallRNAs signature performed with an AUC 
of 0.78 (Figure 9.4-2 C). On the other hand, the same signature performed even better in 
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classifying Alzheimer’s disease and controls in the brain region with an AUC of 0.89 (Figure 
9.4-2 F). This result suggests that we can use the non-invasive techniques with these 
smallRNAs signatures to perform a good diagnosis between Alzheimer’s disease and 
controls. 
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9.5 Functionally enriched piRNAs and miRNAs gene target 
pathways 
9.5.1 Pathway analysis of miRNAs signature functional targets  
 
Figure 9.5-1 Signature miRNAs-gene targets regulatory network 
A. Signature miRNAs are represented by blue circles and the orange circles represent the 
gene targets of the corresponding miRNAs. The grey edge connecting two miRNAs 
represents that there is a regulatory link between the two entities. The network is generated 
by the webtool miRwalk (v 3.0) [318, 319]. The most common targets of all miRNAs are 
called as hub genes. B. Pathways that are enriched in all genes-targets of the three miRNAs 
signature. C. Pathways that are enriched in only hub gene-targets of the three miRNAs 
signature. 
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In order to look at the involvement of the miRNAs target genes in the relevant biological 
pathways that shows the disease characteristics, pathway analysis of the confirmed target 
genes from the three miRNAs is performed. As one miRNA can regulate several genes and 
one gene can be regulated by several miRNAs [320], it forms a complex network of 
functionally enriched gene targets of the miRNAs. The miRNAs-gene target network for the 
signature miRNAs is shown in Figure 9.5-1 A. The analysis of all the confirmed targets of the 
three signature miRNAs revels the association of the target genes with pathways that are 
highly relevant to Alzheimer’s disease pathogenesis. Some of the major players that are well 
known are pathways linked to inflammatory processes [321-330] various signalling pathways 
like IGF1[331-336] and mTOR signaling [337, 338] and to HIF1alpha related hypoxia [339-
342] (Figure 9.5-1 B). After investigating all the targets of the miRNAs signature, a subset of 
gene targets that are commonly regulated by all the three signatures also termed “hub 
genes” were investigated (Figure 9.5-1 A). Coincidently, very similar and common pathways 
were identified by these hub genes (Figure 9.5-1 C) and mostly involved HIF1α mediated 
hypoxia, several pathways that are related to inflammatory processes and unique pathways 
like regulation of androgen receptor activity [343, 344] that are shown to have a role in 
Alzheimer’s disease. 
9.5.2 Functional annotation of piRNAs signature targets 
The other smallRNAs in the signature are the three piRNAs and till date, unlike miRNAs, the 
functions of piRNAs in the brain are still not well studied.  One important role or function of 
these piRNAs is the silencing of the transposon elements [345-347] along with maintaining 
the integrity of the genome [348]. The piRNAs are conserved poorly evolutionary among the 
various species [349]. In the human genome, a majority of the piRNAs (~70%) comes from 
the distal intergenic regions (Figure 9.1-2 A top right pie chart). However, in comparison to 
the globally expressed piRNAs,  the piRNAs that are expressed in the CSF exosomes, a 
larger number of the expressed piRNAs comes from the first exons (Figure 9.1-2 A bottom 
right pie chart). It has also been reported recently that the smallRNAs coming from the first 
exon are predictive of disease [306]. This is also true for the three piRNAs in the signature 
that are also mainly coming from the first exon and the targets of the genes, for example 
neurexin 1 (NRXN1) [350-352] have been reported to be involved in Alzheimer’s disease 
(Table 9-4).  
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Table 9-4 Detailed Annotation of CSF piRNAs signature with their Alzheimer’s disease 
associated alterations 





71851050|+ Distal Intergenic CARTPT [353] 
hsa_piR_019949|chr11:122559947-
122559977|+ 
Exon (uc021qrq.1/uc021qrq.1, exon 1 
of 1) UBASH3B [354] 
hsa_piR_020364|chr10:72972395-
72972420|- Distal Intergenic PLA2G12B [355] 
hsa_piR_020364|chr14:102317092-
102317117|+ Promoter (<=1kb) ZNF839 [356] 
hsa_piR_020364|chr17:8227039-
8227064|- 3' UTR LINC00324 [357] 
hsa_piR_020364|chr2:50936204-
50936229|- 
Intron (uc021vhg.1/9378, intron 21 of 
22) NRXN1 [358] 
hsa_piR_020364|chr6:26554122-
26554147|+ 
Exon (uc021ynp.1/uc021ynp.1, exon 1 
of 1) HMGN4 [359, 360] 
hsa_piR_020364|chr6:27177263-
27177288|- 
Exon (uc021ypd.1/uc021ypd.1, exon 1 
of 1) HIST1H2BK [361] 
hsa_piR_020364|chr6:27237619-
27237644|- 
Exon (uc021ypk.1/uc021ypk.1, exon 1 
of 1) POM121L2 [362] 
hsa_piR_020364|chr6:27293892-
27293917|+ 
Exon (uc021ypq.1/uc021ypq.1, exon 1 
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9.6 3C-seq Quality control and mapping statistics 
9.6.1 3C-seq library quality 
The sequencing is performed on Illumina HiSeq2500. As the project was the pilot project and 
the initial input was low, the quality of the data was not of high resolution. The data is still of 
very good quality. 
Table 9-5 General sequencing statistics 
Sample Duplicates (%) GC content (%) 
Average sequence 
length (bp) 
Initial number of 
reads 
NeuNneg_R1 78.76 43 112 144279949 
NeuNneg_R2 75.21 43 113 144279949 
NeuNpos_R1 90.79 42 93 215566744 
NeuNpos_R2 87.19 43 94 215566744 
 
The average number of sequencing reads for the NeuNneg samples are around 144 million 
reads and 215 million reads for the NeuNpos samples. The overall %GC of all bases in all 
sequences were found to be similar in both samples with nearly all of them to be 43%. 
Although the initial number of reads is higher in the NeuNpos sample compared to the 
NeuNneg samples, the average sequence length of the NeuNneg samples were higher than 
NeuNpos samples (Table 9-5). The overall quality of the samples for both NeuNneg and 
NeuNpos samples is found to be good with average quality per read to be around Phred 
score of 35 (Figure 9.6-1 A). The x-axis represents the length of sequencing reads and the 
y-axis shows the Phred quality score. The Phred quality [255] 𝑄𝑃ℎ𝑟𝑞𝑚 is given by  
 
𝑄𝑃ℎ𝑟𝑞𝑚 = −10 log10 𝑆𝑟 
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Table 9-6 Relationship of base call accuracy and Phred quality score 
Phred quality score (𝑸𝑷𝑷𝑷𝑷𝑷) Probability (𝑷𝑷) Base call accuracy (%) 
10 10-1 90.000 
20 10-2 99.000 
30 10-3 99.900 
40 10-4 99.990 
50 10-5 99.999 
 
There is however a small percentage of reads with poor quality, but they are still above the 
recommended a good quality threshold of a Phred score of 30 (Table 9-6). The level of 
duplicates is also normal for a 3C-seq library [364] with 15% of library have an enrichment 
artifact peak around 10000 duplication level (Figure 9.6-1 B). The plot shows the number of 
duplicates on the axis and y-axis representing the percentage of library containing those 
duplicate numbers of reads.  The high duplicate number of reads at the end of the plot 
(Figure 9.6-1 B) showed in solid lines shows the high enrichment or PCR amplification of 
certain interactions. Dotted line representing de-duplicated set of reads, however, 
disappears the peak representing that the library does not contain any contaminant or any 
high sequencing based technical duplication. 
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Figure 9.6-1 Quality score distribution over all sequences and duplicate sequences 
The distributions of over-represented sequences are less in non-neuronal samples 
compared to the neuronal samples (Figure 9.6-2). It might be due to some biological 
sequences or just PCR amplification artifacts. These are however taken care of in the 
normalization step. 
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Figure 9.6-2 Overrepresented Sequences 
9.6.2 3C-seq iterative mapping and iterative correction 
After the through quality check for the 3C-seq raw data, the reads were mapped to the 
mouse genome (mm10). Due to the use of the four cutter DpnII, average fragment sizes are 
around 300-500 bp and with 101bp sequencing paired-end reads, only  20% of the reads are 
a valid read pair that contains the restriction enzyme junction.  The reads were trimmed to 
contain the largest potential ligation junction. The reads are then mapped iteratively starting 
with the length of 25bp from 5’ end and increasing 5 bp for every subsequent iteration till the 
length of the read (section 8.9.2 above). Approximately 52% reads were mapped to the 
neuronal samples and 67% reads were mapped for non-neuronal samples (Table 9-7). After 
all the filtering of various types, approximately 12.5 M and 1.8 M reads were found to be 
uniquely valid pairs of neuronal and non-neuronal samples. The iterative correction was then 
performed to reveal the relative interaction probabilities both cis (intra) and trans (inter) 
chromosomal interactions.  
Table 9-7 Iterative mapping results 
 General HiC terms NeuNneg NeuNPos 
Mapping 
Side 1 mapped 96027256 111813998 
Side 2 mapped 95512770 111460268 
Total Reads 
Reads without unused chromosomes 102270189 120752492 
Reads removed unused chromosomes 0 0 
DS reads Total DS reads 89269837 102521774 
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DS + SS 102270189 120752492 
SS reads removed 13000352 18230718 
Reads removed 
Same fragment 70549394 81622867 
Self-circles 3870368 2706058 
Dangling ends 66665741 78902539 
Extra dangling ends 9082595 7152212 
Error 13285 14270 
Valid pairs 
Total valid pairs 9637848 7152212 
Duplicates removed 7852492 13746695 
Unique valid pairs 1785356 12567075 
 
9.7 Three dimensional landscape of neuronal and non-neuronal 
populations 
9.7.1 Chromatin interaction patterns in the two types of CA1 cell 
population 
Another way to understand the neurodegenerative disorders is to look at how the various 
neuronal and non-neuronal cells interact. To explore the three dimensional architecture of 
the neuronal and non-neuronal cells, 3C-seq was performed. The two libraries of 
approximately 144M and 215 M (Table 9-5) reads were generated for non-neuronal and 
neuronal samples. The samples were iteratively mapped (Table 9-7), corrected and 
normalized using iterative correction (balancing) [296] and final contact matrices were 
produced. As expected, the inter-chromosomal interactions are higher compared to the intra-
chromosomal interactions (Figure 9.7-1). Even with higher number of reads in the non-
neuronal population (Figure 9.7-1 Left), the numbers of looping interactions are higher than 
the neuronal population (Figure 9.7-1 Right). The alternative interaction pattern also reflects 
the compartments in the two populations [365, 366]. 
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Figure 9.7-1 Chromatin interaction contact maps for non-neuronal and neuronal population 
9.7.2 TADs in neuronal and non-neuronal population 
To understand the higher order chromatin structure in the neuronal and non-neuronal 
populations, Topologically Associating Domains (TADs) were identified for all the 
chromosomes using the insulation score [367] and the directionality index [209]. However, 
TADs calculated with the insulation scores were considered due to better similarities with the 
published data [366, 368-370]. The number of TADs in the neuronal population is marginally 
higher than the non-neuronal population (Figure 9.7-2 (inset)). This may not affect the overall 
interaction pattern, but it may affect certain genes which may be specific to those 
populations. This will be further explained in the section 9.7.4 below. The TADs from the 
mouse mm9 cortex are taken from the original published study [209] with 40kb resolution.  
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Figure 9.7-2 Number of Topologically Associating Domains (TADs) for neuronal and non-
neuronal populations 
9.7.3 Local interaction patterns in chromosome 9 (mm9) for neuronal 
and non-neuronal populations 
The chromatin interactions tend to stay within the same TAD and inter-TAD interactions are 
not that common. This can be seen in both neuronal and non-neuronal population. However, 
the density of neuronal inter-tad interactions is less than the non-neuronal population (Figure 
9.7-4). This is an interesting finding as that means there is more long range looping in the 
non-neuronal population compared to the neuronal population. The result, however, should 
be considered with precaution given the low sequencing depth. 
 
The difference in interaction pattern can be observed clearly from the Figure 9.7-5. There 
are many places, for example, the region on chromosome 9 with genomic location 
chr9:10,000,000-40,000,000 and chr9:40,000,000-55,000,000 where the genes that are the 
boundary of the TADs has a lower expression in the neuronal population compared to the 
non-neuronal population (Figure 9.7-5). This may be due to the miRNAs that are present in 
the region or genes may be regulated by H3K27m3 peaks (denoted by the Cbellum 
H3K27me3 [371, 372]) Track. On the other hand, the genomic region in the neuronal 
population chr9: 90,000,000-92,000,000 (marked by red arrow in Figure 9.7-5) has higher 
neuronal interactions compared to the non-neurons and a distinct reduction in the number of 
H3K27m3 peaks in the region. This might suggest that the high interaction pattern may be 
between the TSS of the expressed genes and the H3K4me1 marks. The targets of miRNAs 
that are involved in neurodegeneration from example with the Alzheimer’s disease (miR-30a-
5p [373], let-7i-5p [374], 181a-5p [375] etc.) are also present in the region (for example: Sik2 
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(SIK2 salt inducible kinase 2)) with links to neurodegeneration [376-378]. A thorough 
analysis needs to be performed in the next phase of the study. 
 
 
Figure 9.7-3 Figure 9.7-4 Local interaction patterns in chromosome 9 (mm9) for neuronal 
and non-neuronal populations 
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Figure 9.7-5 CA1 interactions looping profiles in neuronal and non-neuronal population 
9.7.4 Interactions pattern near the BACE1 gene 
One of the pathological hallmarks of Alzheimer’s disease (Alzheimer’s disease) is the 
formation of the Aβ plaques. BACE1 plays the key role in initiating the formation of these Aβ 
plaques [379-382]. The interaction profile of the region containing the BACE1 genes 
becomes crucial to understand. For this, a 5 MB region looping interaction profile is 
generated (Figure 9.7-6). The same neuronal over non-neuronal interaction values are 
plotted as the heatmap. As mentioned in section 9.7.2 above that there is a marginal 
decrease in the number of TADs in the neuronal and the non-neuronal population. The TAD 
in the genomic location of the BACE1 gene is missing the non-neuronal population, while the 
TAD in the neuronal population is expanded to have more interactions. However, the TAD 
left to the BACE1 gene in the non-neuronal population shows a higher number of looping 
interactions (chr9:44,5000,000–45,000,000) as it is more bluish. Also, the bins containing the 
BACE1 gene have higher interactions in the neuronal samples compared to the non-
neuronal samples. The gene density (Figure 9.7-6: Refseq genes) and density of enhancers 
(H3k4me1) marks are also higher near the BACE1 gene resulting in an increase in the 
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looping interaction of TSS in the neuronal samples. The absence of TADs around the 
BACE1 gene in the non-neuronal population, and, an increase in the looping interactions of 
the TSS and the enhancers of the BACE1 genes in the neuronal population suggesting the 
role of 3D genome organization in the Alzheimer’s disease. At this point, the results should 
be very carefully examined as this is the pilot study that resulted in the low number of 
mapped reads to perform the analysis at a higher resolution.  
 
 
Figure 9.7-6 The interaction pattern in the vicinity of the BACE1 gene 
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10.   Discussion 
The work reported in this thesis provides an outlook into the fast progressing 
neurodegenerative disorders especially the Alzheimer’s disease. It shows the need for the 
development of not only the sensitive, accurate, cheap and non-invasive biomarkers that can 
help in the diagnosis, prognosis, and prediction of the onset of a disease, but also focuses 
on the development of the statistical and computational pipelines and toolkits to provide a 
way to replicate the results and perform new analysis without introducing new technical 
biases. It also sheds a light on how the chromatin is organized in the genome and basic 
differences in the looping interactions between the neuronal and non-neuronal cell 
populations by the use of the latest techniques like 3C-seq. 
 
The discussion is divided into two parts, one for each aim similar to methods and results 
sections to provide a clear understanding and interpretation of the work performed in line 
with the current published research. The conclusion finally provides a bird’s eye view of the 
study that wraps up the two aims and provides a bigger picture to the current state of the 
biological question that is investigated in this study.  
10.1 miRNAs and piRNAs as biomarker for Alzheimer’s disease 
Neurodegenerative disorders, for example, Alzheimer’s disease and mild cognitive 
impairment that are identified by cognitive decline over a period of time and ultimately 
resulting in dementia, in general, diminishes the quality of life and affects not just the 
individual suffering from it but everyone around them [383-387]. At present, the goal in the 
research community is to develop biomarkers for the diagnosis [388-390] and prognosis 
[391-394] of these neurodegenerative disorders as the underlying disease mechanism that 
may help find good and effective biomarkers remains poorly understood. There has been an 
increasing number of reports [395-397] on circulating miRNAs and piRNAs as potential 
biomarkers for neurodegenerative disorders, providing much needed abilities for early 
diagnosis, disease distinction, disease prognosis and possible therapeutic benefits. During 
the course of my studies, I investigated a small number of miRNAs and piRNAs as a putative 
signature that shows both diagnostic potential (Figure 9.2-4) as well as the disease 
progression from MCI to Alzheimer’s disease (Figure 9.3-2). 
  
I focused my study to identify the potential biomarker signatures for the Alzheimer’s disease 
that uses the expression level of small noncoding RNAs (for diagnosis and prediction of the 
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disease) by putting significant effort into the characterization of the small noncoding 
RNAome in humans. In order to identify a fairly non-invasive biomarker signature, the first 
step is to check the content of small noncoding RNAs from the CSF exosomes as it has 
been reported recently that CSF exosomes contain proteins and small noncoding RNAs that 
can be used as biomarker signature [58, 69, 398] (Section 6.4 above) for these 
neurodegenerative disorders. After successfully establishing that CSF exosomes contain the 
small noncoding RNAs (Section 8.1 above), another challenge was to check their 
expression. With the advent of NGS technologies, this was made possible experimentally. 
However, there were many bioinformatics challenges to quantify and summarize the 
expression of these small noncoding RNAs. These small noncoding RNAs often originates 
from multiple locations in the genome. This leads to the problem of uniquely aligning a 
particular small noncoding RNA that has multiple genomic origins to the reference genome. 
Traditional mapping software uses the common strategy of mapping (aligning) the small 
noncoding RNA reads to a reference genome, which normally leads to poor alignment 
(mapping) percentage as they either discard the multiple aligned small noncoding RNAs or 
randomly choose one of the mapping (normally the first alignment found). To address such 
issues, I successfully developed a pipeline (Section 8.3 above) that takes care of the 
multiple genomic origins of these small noncoding RNAs in the genome and provides the 
correct expression for these small noncoding RNA molecules.  
 
From there, identification of informative small noncoding RNAs among the thousands of 
small noncoding RNAs was the challenge. I applied various statistical and machine learning 
approaches (Section 8.4 above and 8.5 above) to achieve this task where in the end, I 
identified a signature containing three miRNAs and three piRNAs. I further evaluated their 
diagnostic performance (Section 9.2.5 above) and the disease progression performance 
from MCI stable to MCI Alzheimer’s disease (Section 9.3.3 above). I also compared the 
diagnostic (Alzheimer’s disease vs. CL) performance of these small noncoding RNAs 
signature to the existing protein based clinical biomarkers specifically the levels of pTAU and 
Aβ42/Aβ40 ratio for the same human samples (Section 9.2.2 above). In the end, the small 
noncoding RNAs signature alone had good diagnostic and predictive abilities (Figure 9.2-4 C 
and Figure 9.3-2 C). Moreover, the diagnostic ability of these signatures increased 
tremendously by the use of the combination of both the protein based clinical biomarkers 
and the small noncoding RNAs signature (Figure 9.2-4 D).  
 
Another important task is to find non-invasive biomarkers which can diagnose brain 
conditions as accurately as possible. The hypothesis here is that whether the expression of 
the small noncoding RNAs present in the bodily fluids such as blood, saliva or urine can also 
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be used as a biomarker signature. In order to check this hypothesis, I looked at the 
expression level of the particular small noncoding RNAs that I obtained as a biomarker 
signature (Section 9.2.5 above) in plasma exosomes. Almost all the small noncoding RNAs 
signature was expressed in plasma exosomes. Moreover, the diagnostic ability of the small 
noncoding RNAs signature in plasma exosomes was also good (Figure 9.4-2 A, B, C). 
Finally, I also wanted to check that the expression level of the small noncoding RNAs 
signature obtained from CSF exosomes reflects some (not all) changes in the brain. To this 
end, I checked the expression level of the small noncoding RNAs signature in brain tissue. 
All six small noncoding RNAs signature were expressed in the brain tissue. Furthermore, the 
diagnostic ability of these small noncoding RNAs signature to classify between Alzheimer’s 
disease and controls was excellent (Figure 9.4-2 D, E, F). This suggests that the small 
noncoding RNAs can be targeted as biomarker candidates for the Alzheimer’s disease 
diagnosis.  
 
Finally, in order to get a better understanding of the functions of these small noncoding 
RNAs (miRNAs and piRNAs); I analyzed the role their targets play in the regulatory 
machinery of the disease pathway. I characterized these small noncoding RNAs from their 
target genes to find functionally similar co-expressing smallRNAs-gene target pairs that can 
be used as potential therapeutic drug targets for the Alzheimer’s disease. For all small 
noncoding RNAs (miRNAs and piRNAs) signature, I report plausible functional targets that 
have a role in the Alzheimer’s disease pathogenesis (Figure 9.5-1).  
10.1.1 Characterization of CSF exosomes  
Most neurodegenerative diseases including Alzheimer’s disease can be characterized by the 
aggregation of certain proteins in the brain and can be only be confirmed after the port-
mortem analysis of the brain tissue. Targeting the pathways that lead to the aggregation of 
these proteins are reported to have therapeutic potential [399-401]. Detection of these 
aggregated proteins in the brain is also possible by the use of neuroimaging techniques 
[402] which led to the rapid advances in the field of neuroimaging and the development of 
the neuroimaging markers [403-405]. However, the accuracy and sensitivity of these 
neuroimaging markers are still poor [406]. Identification of protein and small noncoding 
RNAs based markers [407, 408] offer a complementary approach for the characterization 
and early detection of the neurodegenerative disorders. These markers can be measured 
from bodily fluids like Cerebrospinal fluid (CSF), peripheral blood, saliva, breastmilk or urine 
and can be used in the clinics as non-invasive biomarkers. 
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Recent studies have shown that small noncoding RNAs especially miRNAs and piRNAs are 
present in the bodily fluids as free smallRNAs or within the extracellular vesicles (EVs) like 
exosomes [409-413]. One of the major challenges that other researchers and I have faced is 
the lack of standard operating protocols in the collection, extraction, and handling of bodily 
fluids for RNA isolation. The lack of standardization affects the downstream analysis as it 
can introduce major biases. Few studies [414-416] tried to address this issue, but still, there 
is an urgent need for standardization of such protocols for multi cohort studies. Furthermore, 
development and open access to the manufacturing standards, clinical certification, and 
standard data analysis protocols should be encouraged. 
 
One drawback of CSF based biomarkers is the complicated and invasive collection 
procedure of CSF (through a lumbar puncture (Section 8.1.1 above)). On the other hand, a 
fairly practical and non-invasive collection procedure of peripheral blood makes the blood 
based biomarkers a promising candidate for the diagnosis of Alzheimer’s disease. There are 
few studies reported recently on the development of the non-invasive biomarkers from blood 
plasma [417-419] or blood serum [420, 421]. However, a major caveat in the development of 
the non-invasive blood based biomarkers is the concentration of the Alzheimer’s disease 
pathology related proteins in the brain that is reflected at a far lower amount in the blood 
than compared to CSF. For example, the concentration of TAU proteins in CSF is ~250 
pg/ml [422], while the concentration of TAU measured in blood plasma is ~5 pg/ml [423]. 
This makes the quantification of TAU proteins in blood plasma difficult as the TAU proteins 
need to be isolated from blood plasma containing highly abundant proteins such as albumin 
that has a concentration of ~50 mg/ml [424]. 
 
SmallRNAs from CSF offers more and detailed information about the brain than the 
smallRNAs coming from blood plasma or serum as the extracellular matrix of the brain is in 
direct contact with the CSF [425]. Many smallRNAs detected in CSF exosomes are also 
highly expressed in the brain, suggesting the possible communication link between the brain 
and distal organs by the use of exosomes [426]. The cellular and exosomal small noncoding 
RNAome profile is found to be highly correlated as reported in the section 9.1.4 above and 
shown in the  
 
Figure 9.1-4. I also investigated the profile of mature miRNAs in whole cells and exosomes. 
Mature miRNAs are derived from the precursor miRNAs. Moreover, there is no mechanism 
known yet that reports which mature miRNAs arm is functional [427, 428]. One hypothesis is 
that after the stem loop of premature miRNAs is cleaved by the Dicer, two mature strands 5p 
and 3p arms are produced. Depending on the stability of either or both arm may be 
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functional and the unstable arm is degraded [429, 430]. It has been reported previously [431, 
432] that the inactive strand of the miRNAs are cleared by the use of exosomes and hence 
most miRNAs found in the exosomes are for degradation. However, as shown in the Figure 
9.1-3 there is no such pattern observed. Both the cellular miRNAs and exosomal miRNAs 
showed the same expression pattern, whether it be the active or inactive arm. This 
relationship also strengthens the idea that the small noncoding RNAs in CSF exosomes in 
some part reflects the small noncoding RNAs snapshot of the cell of origin which may reside 
in the brain.   
10.1.2 Characterization of NGS analysis and small noncoding RNAs 
Profiling of small noncoding RNAs using the next generation sequencing technologies is a 
challenging task. This is due to the duplication or multiple origins of several small noncoding 
RNAs within the genome. Many published tools [302, 303, 433-439] for the profiling of the 
small noncoding RNAs either completely failed to address or poorly address the multi-origin 
of the small noncoding RNAs. Briefly, their mapping strategy included mapping the small 
noncoding RNA reads to the full reference genome and then annotating the mapped reads 
with the annotation database or file. During this process, they either discard the multiple 
mapped reads completely or use only the first or a randomly mapped location strategy. This 
leads to a significant drop in assessing the expression of some of highly expressed small 
noncoding RNAs. For example, one of the highest expressed miRNA in the brain hsa-miR-
181a-5p [303, 440-443] is either completely missing or reported extremely low read counts 
using the current approach. However, there are other tools [444-447] that offer a different 
strategy quantified miRNAs correctly, but do not quantify other small noncoding RNAs such 
as piRNAs, snRNAs or snoRNAs.  
 
Thus, I developed my own mapping strategy. I used the custom reference genome created 
by the sequences of the small noncoding RNAs and mapped the small noncoding RNA 
reads to this custom reference genome with iterative mapping strategy shown in Figure 
8.3-1.  The mapping pipeline (GJSrMap) [253] described in detail in section 8.3 above, has 
several advantages over the existing pipelines and available tools. One of the biggest 
advantages is the modularity of the pipeline. All of its sections are customizable from the 
choice of alignment software (section 8.3.3 above) to the building of the custom reference 
genome (section 8.3.1.3 above) and the annotation of the smallRNAs (section 8.3.4.1 
above). By default, the pipeline is optimized to run a high performance cluster computing 
(HPCC) system, but it can easily be customized to run on a local server or computer. The 
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pipeline also provides the logs and statistics for every iteration related to the mapping of the 
reads.  
 
A big part of the pipeline is the quality control steps taken to ensure the clean and high 
accuracy during the mapping and read counting process. First, the fastQ files are checked 
for the quality of sequencing. Then, before the alignment, adapters are trimmed and the 
reads with low quality scores are filtered out. Afterward, alignment of reads to the 
customized reference genome is performed iteratively. Final BAM files are filtered to remove 
the low quality mapping and sorted for the counting. After read counting is performed, the 
reads are assigned to each small noncoding RNAs class such as miRNAs and piRNAs. Both 
raw and normalized reads (Counts per million (CPM) [448] as default) are provided for the 
assessment of the mapping. Future versions of the pipeline will include the quantile, median 
and variance stabilized normalization (default) methods (section 8.4.1 above).  
 
The pipeline also provides a detailed summary of mapping quality, library size distribution, 
distribution of small noncoding RNA classes found in the sequencing reads and the 
distribution of individual small noncoding RNAs within each class (Figure 8.3-2). Samples 
with low uniquely mapped read counts are recommended to be removed from the further 
downstream analysis as do not offer any information. The pipeline can distinguish between 
the real useful biological products and degradation products and provides additional 
information on the distribution of the special infrastructural small RNA classes such as 
rRNAs, pre-mature miRNAs, and snoRNAs (section 6.5.2 above). If they are present in high 
percentages, then the RNA isolation or the library preparation part needs to be tested.  
 
In the CSF data, miRNAs distribution is the most highest as expected, but surprisingly 
second most abundant class of small RNAs are the piRNAs (Figure 9.1-2). All the top five 
miRNAs in the human CSF samples are reported to play a role in neurodegeneration. MiR-
10-5p is reported to be involved with Sporadic Amyotrophic Lateral Sclerosis, Parkinson 
disease and Alzheimer disease [301, 449]. MiR-22-3p is reported to regulate cell 
proliferation [450] and inhibits cell apoptosis [451]. MiR-204-5p is reported as a biomarker 
candidate in Frontotemporal Dementia (FTD) [452] and as a therapeutic target in 
endometrial carcinoma [453]. MiR-26a-5p is reported to regulate the expression of inducible 
nitric oxide synthase in human osteoarthritis chondrocytes [454] and play an active role in 
tumorigenesis [455] growth and in multiple sclerosis [456]. MiR-10b-5p is involved in 
Huntington’s disease [457] and breast cancer [458]. However, not much known about the 
roles of piRNAs and only recently a few studies reported the role of piRNAs in Alzheimer’s 
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disease [122, 459] in cancer [460-462] in cardiac regeneration [463] and retinal 
degeneration [464].  
 
In the human genome (Figure 9.1-2), 70.6% of piRNAs comes from the distal intergenic 
regions, 4.1% from the promoters of the genes and only about 1.2% comes from the 1st exon 
of a gene. Compared to piRNAs from the CSF exosomes, I found that 61% of piRNAs 
originate from 1st exon of a gene, 18.5% from the promoters of the genes and only 13.5% 
from the distal intergenic regions of the genome.  A recent study [306] in cancer research 
reported that the smallRNAs from the 1st exons can distinguish between cancer and healthy 
individuals. The ones near the TSS are also found to be conserved between tissues. The 
three piRNAs from the biomarker signature has origin from the protein coding genes that are 
associated with Alzheimer’s disease (Table 9-4). This shows that there is a great need to 
study these classes of small noncoding RNAs apart from miRNAs to get a complete picture 
of the regulation of the genes that are involved in the disease pathology. 
10.1.3 Role of clinically established CSF biomarkers for Alzheimer’s 
disease diagnosis 
At the core of Alzheimer’s disease pathology are the key molecular hallmarks amyloid-beta 
(Aβ) peptides and phosphorylated TAU, which are the key components of insoluble plaques 
and tangles respectively. Both have been closely correlated with the Alzheimer’s disease 
progression. One of the major functions that are disrupted [465, 466] in the pathogenesis of 
Alzheimer’s disease is the interaction of various signalling pathways believe to regulate the 
phosphorylation of TAU [467-470]. The highly soluble TAU protein when gets hyper-
phosphorylated particularly mediated by CDK5 [471, 472], dissociates from is microtubules 
in the axons and form paired helical filaments (PHF) [473, 474] which are insoluble 
aggregates and believed to cause axonal transport impairment [475]. This in turn is believed 
to cause neuronal dysfunction [476] and cognitive decline in Alzheimer’s disease [477, 478]. 
 
One of the major updates to the Alzheimer's Disease Diagnostic Guidelines [479] that were 
included in 2011 by the National Institutes of Health and the Alzheimer’s Association is to 
recognize the potential use of the brain and CSF biomarkers. The use of positron emission 
tomography (PET) scans [480] and cerebrospinal fluid (CSF) analysis to check the elevated 
levels of TAU [481, 482] and/or decreased levels of amyloid-beta (Aβ) [483, 484] in CSF for 
the amyloid plaques and neurofibrillary tangles build up is suggested but not implemented in 
the clinics yet [12, 479, 485, 486].  
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The role of Aβ and TAU from CSF as biomarkers [487-489] has now been validated in many 
population studies [490, 491] and cohorts [492]. Recently, many studies [493-495] have 
shown that Aβ42/40 ratio has better accuracy in the clinical diagnosis of Alzheimer’s disease 
compared to the levels of Aβ40 or Aβ42 alone. It has also been shown that the Aβ42/40 ratio 
is highly correlated to the levels of pTAU in the Alzheimer’s disease patients [496, 497].  In 
line with the current research that is reported, I also found the levels of pTAU and Aβ42/40 
ratio elevated in the Alzheimer’s disease patients compared to the controls (Figure 9.2-1). In 
terms of classification abilities of these protein based clinical biomarkers, I also see a good 
diagnostic performance with an AUC of 0.87 (Figure 9.2-1) for Aβ42/40 ratio and pTAU in 
distinguishing the Alzheimer’s disease patients from controls. An interesting observation 
here is that when compared to each other, pTAU is found to be more informative than 
Aβ42/40 ratio (Figure 9.2-1 inset barplot).  
10.1.4 The CSF miRNA/piRNA signature as biomarker for Alzheimer’s 
disease diagnosis 
One important aspect of the clinically established CSF protein biomarkers (Aβ40, Aβ42 TAU, 
pTAU and Aβ42/40 ratio) [498] along with positron emission tomography (PET) scans is that 
they are biased towards the clinical hallmark pathology of Alzheimer’s disease i.e. the build-
up of insoluble amyloid plaques and neurofibrillary tangles in the brain. However, other 
methodologies such as exploring epigenetics mechanisms that might explain alternative part 
of Alzheimer’s disease pathogenesis and might provide other methods for disease 
diagnosis, prognosis and therapeutic targets [499] should be investigated. Small noncoding 
RNAs like miRNAs and piRNAs are present in bio fluids like CSF and blood and are shown 
to have both diagnostic and prognostic abilities as a biomarker for Alzheimer’s disease. 
 
Out of all the small noncoding RNAs, miRNAs are the most studied ones. Their abundance 
and stability mark their key features to be a good biomarker candidate [500]. Many studies 
have reported miRNAs as novel and non-invasive biomarkers for Alzheimer’s disease [501-
506] by the use of various approaches. One array based study reported miRNAs in brain 
and CSF from Alzheimer’disease patients and non-demented controls and could identify 60 
differentially expressed miRNAs in CSF [502]. Another recent study investigated eight 
selected miRNAs in CSF from Alzheimer’s disease patients and reported lower miR-146a 
levels in Alzheimer’s disease [507]. In a targeted approach miR-let-7b was found to be 
increased in the CSF from Alzheimer’s disease patients [508]. Another study employed the 
array based nano-string technology to study miRNAs level in CSF from Alzheimer’s disease 
patients and identified miR-27a-3p to be reduced in the CSF from Alzheimer’s disease 
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patients [509], while miR-100, miR-103 and miR-375 levels in CSF were found to 
discriminate Alzheimer’s disease patients from non-demented individuals [276]. Another 
group of scientists reported that the loss of miR-9, miR-137 miR-181c and miR-29a/b-1 
increases the levels of the rate limiting enzyme Serine palmitoyltransferase (SPT) resulting 
in the increased levels of Aβ [510]. It has also been shown that the loss of miR-29a/b-1 
cluster resulted in elevated levels of BACE1 gene and consequently levels of Aβ in sporadic 
Alzheimer’s disease [511]. 
 
Recently, another class of small noncoding RNAs, piRNAs has gained traction. Although, 
many studies already reported their various functions such as post transcriptional regulation 
of protein coding genes and stability of mature mRNAs [512], chromatin stability [513, 514], 
regulation of epigenetic mechanisms [515, 516] and most importantly suppression of 
transposons [347, 517, 518]. First reports have only been recently published that piRNAs 
also play a role in the pathogenesis of various disease [122, 459, 519-522]. Some reported 
piRNAs with their respective target genes that are shown to play a role in Alzheimer’s 
disease are piR-38240 (cytochrome c), piR-34393 (karyopherin subunit alpha 6), and piR-
40666 (RAB11A) having an inverse gene expression relationship [122].  
 
In this study, I developed a specialized mapping pipeline (section 8.3 above) and used 
various statistical and machine learning algorithms (section 8.5 above) to obtain a set of 
miRNAs and piRNAs that can be useful in early diagnosis, disease distinction, disease 
prognosis and possible therapeutic benefits in Alzheimer’s disease. Identification of a few 
most informative miRNAs and piRNAs from the entire small noncoding RNAome with a 
limited number of samples was a challenging task. First, I applied the Measure of Relevance 
(MoR) procedure [275] and a reliability test [276] to obtain a significantly reduced set of 
informative miRNAs and piRNAs that are expressed in at least 95% of the samples (section 
8.5.1 above). After the removal of the uninformative smallRNAs, a more sophisticated 
variable ranking is calculated using various machine learning algorithms that provide a mean 
ranked score for each informative signature (section 8.5.1 above). I chose a threshold of 
0.30 after the discussion with experts in machine learning and filtered out the miRNAs and 
piRNAs that were found below this threshold. The miRNAs and piRNAs are also checked if 
they are confounded by age and gender by using MANCOVA analysis (section 8.5.2 above).   
 
After taking all the measures to ensure the effectiveness of the miRNAs and piRNAs, I got 
three miRNAs, namely hsa-miR-27a-3p, hsa-miR-30a-5p, miR-34c-3p and three piRNAs, 
namely hsa-piR-019949, hsa-piR-020364 and hsa-piR-019324 as the putative biomarker 
signature. In order to avoid redundancy of the information provided by these small 
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noncoding RNAs signature and protein based clinical biomarkers used in the study (pTAU 
and Aβ42/40 ratio), I performed the correlation analysis (section 9.2.4 above Table 9-1). I 
found that they do not correlate which means that they provide information on a different 
aspects of the Alzheimer’s disease pathology. This is also very promising as in the future a 
combination of both types of markers can provide a bigger picture rather than an incomplete 
picture by looking at just the individual marker’s diagnosis and prognosis. From here, I 
investigated the diagnostic abilities of the miRNAs and piRNAs signature. I developed a 
random forest model by training the model on cohort 1 data (Table 9-1 row 1) containing 23 
Alzheimer’s disease and 38 control samples. I then used a 10 fold cross-validated approach 
to test the performance of the model (details of the entire procedure is mentioned in section 
Model selection and performance) on an independent replication cohort 2 (Table 9-1 row 2). 
Surprisingly, miRNAs alone signature performed very close to a random model (Figure 9.2-4 
A), while piRNAs signature performed with a high classification accuracy (Figure 9.2-4 B). 
When both miRNAs and piRNAs signature was checked together, a marginal (1%) increase 
in performance to the piRNAs is observed (Figure 9.2-4 C). As the protein based clinical 
biomarkers and the small noncoding RNAs signature provide different information (Section 
9.2.4 above), I looked at the combined power of both types of signature. The combined 
signature performed significantly better to the point of almost perfect classification of 
Alzheimer’s disease and controls (Figure 9.2-4 D) with an AUC of 0.98. This is very 
promising as it can be a very good diagnostic marker, although it needs to be tested on a 
larger cohort with more patients and age matched controls.   
10.1.5 The predictive power of CSF miRNAs/piRNAs signature from  
MCI to Alzheimer’s disease 
While cost-efficient and reliable biomarkers for correct diagnosis of Alzheimer’s disease are 
important, an equally pressing the issue is the detection of markers that could predict the 
conversion of patients suffering from mild cognitive impairment (MCI) to Alzheimer’s disease 
[523]. To this end,  I investigated the predictive abilities of the small noncoding RNAs 
signature in a separate predictive replication cohort 3 (Table 9-2) with 17 MCI individuals of 
which 10 years later, 6 individuals progressed to develop Alzheimer’s disease (mciAD) while 
11 did not develop Alzheimer’s disease (mciStable).  
 
When I evaluated the predictive abilities of the small noncoding RNAs signature, miRNAs 
alone signature performed well with an AUC of 0.70 (Figure 9.3-2A). The piRNAs signature 
showed an excellent predictive ability (Figure 9.3-2 B) with an AUC of 0.86. The combined 
miRNAs and piRNAs signature did not demonstrate predictive abilities with an AUC of 0.62 
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(Figure 9.3-2 C). Nonetheless, this shows the excellent diagnostic and predictive abilities of 
the piRNAs signature in Alzheimer’s disease pathogenesis which has not been reported 
earlier. This data suggest that the CSF exosomal miRNAs and mostly piRNAs signature can 
be used to diagnose Alzheimer’s disease patients and might also be suitable to predict MCI 
patients that are likely to convert to Alzheimer’s disease with careful consideration.  
 
10.1.6 Diagnostic properties of CSF miRNA/piRNA signature for plasma 
and brain tissue samples 
So far, I have discussed the diagnostic and predictive abilities of the two types of CSF 
biomarkers: proteins and small noncoding RNAs based markers. These markers are 
reported to be most investigated by the research community and included as the 
recommended biomarkers in the updated guidelines for clinical diagnostic criteria for 
Alzheimer’s disease by the National Institutes of Health and the Alzheimer’s Association 
[479]. However, obtaining CSF is still invasive as compared to other bodily fluids like saliva, 
urine and blood. There has been a significant increase in the number of studies published 
recently reporting the development and potential therapeutic use of blood based biomarkers 
for Alzheimer’s disease [506, 524-527]. Besides the obvious ease of obtaining blood 
compared to CSF, another advantage these blood based biomarkers provide is that they can 
be obtained in higher volume and are more economic than obtaining CSF. However, this 
also means that the expression of the proteins and smallRNAs that are measured from blood 
based techniques will be diluted and specificity to the brain might not be correlated. The 
technological recent advancements in the field have led to better and more accurate 
detection of these proteins and smallRNAs from blood that can be used as biomarkers for 
MCI and Alzheimer’s disease [78, 528-532]. 
 
To test the diagnostic abilities of the current miRNAs and piRNAs signature found in my 
study, I evaluated them in an independent blood plasma exosomes cohort 4 with 10 
Alzheimer’s disease and 12 control individuals. The miRNAs signature displayed high 
diagnostic abilities (Figure 9.4-2 A) classifying the Alzheimer’s disease individuals from 
controls with an AUC of 0.84. On the other hand, piRNAs displayed some diagnostic abilities 
with an AUC of 0.67 (Figure 9.4-2 B). The combined signature also displayed high diagnostic 
abilities in classifying the Alzheimer’s disease individuals from controls with an AUC of 0.78 
(Figure 9.4-2 C).  The ability of small noncoding RNAs signature to classify Alzheimer’s 
disease individuals from controls in plasma exosomes makes them a potential candidate for 
biomarker signature.  
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It has been reported that the cerebrospinal fluid (CSF) is been in contact with the brain and 
reflects the events happened inside the brain [533-535]. This makes the small noncoding 
RNAs derived from the CSF exosomes highly informative as they can be used to understand 
the processes happening inside the brain [536]. One can also argue that the smallRNAs 
signature from these CSF exosomes can also closely reflect the brain events that can be 
used as markers to identify certain disease symptoms [532, 537-539]. The exosomes (that 
ends up in CSF and blood plasma/serum) may also originate from other cells, including 
diseased neurons and can inform us about the cellular status inside the brain. The 
hypothesis is whether the miRNAs and piRNAs signature I identified from CSF exosomes 
can demonstrate a diagnostic ability to classify Alzheimer’s disease individuals and controls 
in the brain tissue. I downloaded a publicly available datasets and used the samples 
published in that study[317] to look at the diagnostic abilities of the small noncoding RNAs 
signature. The miRNAs signature shows decent diagnostic ability with an AUC of 0.70 
(Figure 9.4-2 D). In comparison to the miRNAs, piRNAs shows excellent diagnostic ability 
with the AUC of 0.97 in classifying individuals with Alzheimer’s disease from controls (Figure 
9.4-2 E). The combined signature also displayed excellent diagnostic ability to classify 
individuals with Alzheimer’s disease from controls (Figure 9.4-2 E).  
 
However, there is still no clear understanding on the origin of smallRNAs in the CSF 
exosomes from the brain. The smallRNAs in the CSF exosomes cannot be assumed to 
come from the neurons exclusively. These smallRNAs can very well come from other non-
neuronal cells, which may alter our understanding of the results. There is also the issue of 
small cohort sizes that only provides a small snapshot from which Alzheimer’s disease 
associated neurodegeneration can be studied. Certainly, a large cohort study is needed to 
confirm the findings I evaluated and reported here. In the meantime, the small noncoding 
RNAs signature (three miRNAs, namely hsa-miR-27a-3p, hsa-miR-30a-5p, miR-34c-3p and 
three piRNAs, namely hsa-piR-019949, hsa-piR-020364 and hsa-piR-019324) may be used 
as a diagnostic tool for Alzheimer’s disease classification and an early measure for disease 
prediction from MCI to Alzheimer’s disease with considerable precautions.  
10.1.7 Functional characterization of CSF miRNAs/piRNAs signature 
The target gene predictions from the miRNAs and piRNAs signature identified many genes 
that play a key role in Alzheimer’s disease pathogenesis related pathways. Some of them 
include the heterodimerization of Retinoid X receptors (RXRs)/Retinoic Acid Receptors 
(RARs) [540] with other receptors and selective targeting of those receptors may help in the 
 Discussion  131 
Aβ removal and better cognition; the mTOR signalling pathways which may play an 
important part in the development of the Alzheimer’s disease [541],  the influence of the 
CD40 and its ligand (CD40L) in the Alzheimer’s disease pathogenesis [542-544] 
inflammation related pathways like IL1-mediated signalling events [325, 326, 328, 545]; IGF1 
pathway [332, 336]; and hypoxia related pathway [339-342] showing to play a role in 
Alzheimer’s disease pathology. I also looked at the set of genes that were the common 
targets for the three miRNAs signature, which I termed as “hub genes” to see if there is a 
core set of pathways that is involved in the disease pathology. I found a very similar set of 
pathways like the hypoxia (HIF-1a and HIF-2a regulated) pathways and calcium signalling in 
the CD4+ TCR pathways [439] playing the role in disease pathology. Since, piRNAs are new 
to this field and very little is known about the target of these piRNAs like we know about the 
miRNAs, a general overview about the piRNAs targets was checked. I found that a majority 
of piRNAs genomewide lies in the distal intergenic regions (Figure 9.1-2 A). On the other 
hand, contrary to the genomewide consensus, the majority of the CSF exosomes piRNAs 
lies in the 1st exons of their targets (Figure 9.1-2 A). The three piRNAs in signature also lies 
in the 1st exons. This is an important finding as it is been shown recently that the smallRNAs 
that comes from the 1st exon of their targets plays an important role in disease prediction 
[306]. Some of the genes the piRNAs are originating from for example NRXN1 [350-352] and 
UBASH3B [546, 547] are also linked with Alzheimer’s disease. Thus the results described in 
section 9.5 above support our hypothesis and cement our belief that the miRNAs and 
piRNAs signature could possibly reflect the interactions of these gene regulatory pathways 
that might play a key role in Alzheimer’s disease pathogenesis. 
10.2 Three dimensional architecture of neuronal and non-
neuronal cells 
In the first aim, I looked at the epigenetic regulation of gene expression and mainly the role 
of small noncoding RNAs involved in the regulatory mechanism. Another way to understand 
the regulation of the gene expression is to study the role of chromatin conformation in 
looping of the genomic elements that are involved in this process of regulation. This field of 
study is quite recent and new mechanisms are constantly being discovered that elucidate 
the role of three dimensional organization of the chromatin involved in controlling the gene 
expression. The hypothesis here is that by studying the chromosomal conformation 
differences between the neuronal and non-neuronal cells, especially at the locations of 
regulatory elements that are crucial in the neurodegenerative disease pathways may open 
up new research frontiers to understand the disease mechanism. For this, we performed a 
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pilot experiment to look at the conformational differences in the chromatin architecture of 
neurons and non-neurons in the CA1 region of wildtype mouse.  
10.2.1 3C-seq library quality assessment, reads alignment and 
balancing 
The overall quality of the samples was good with average read quality about 35 (Phred 
score) for all the samples (Figure 9.6-1). One point to note is that the subset of reads are is 
always going to have variable read quality with few good quality subsets and others with 
poor quality. It is however only considered when the majority of the subset has poor quality 
as they are supposed to be only a very small percentage of total sequences. Low quality 
reads have a small Phred score (Table 9-5) which, if present in large number in the 
sequencing library can be costly in the price of the experiment and may lead to an 
inaccurate understanding of the results. The high quality reads were then aligned to the 
mouse genome (mm9) by using the iterative mapping procedure which led to the mapping of 
52% and 67% in the neuronal and non-neuronal populations respectively (Table 9-6). The 
3C-seq technical artifacts were filtered out and iterative correction and normalization 
(balancing) were performed to enhance the possibility of detecting the looping interactions 
with high probabilities.  
10.2.2 The conformational differences and identification of TADs in the 
neuronal and non-neuronal CA1 populations 
I then looked at the genomewide interaction patterns of neurons and non-neurons in the 
CA1 cells. The initial libraries had approximately 215 and 144 million reads for neuronal and 
non-neuronal population. After iterative mapping, iterative correction and balancing of the 
interaction matrix were performed, I was left with approximately 12.5 and 1.7 million valid 
unique interaction pairs for the neuronal and non-neuronal population. As the experiment 
was a pilot and the quality of the libraries was good, I went ahead to perform the basic 
analysis to look at the differences between the two population cells. The results, however, 
should be very carefully and cautiously interpreted as they may or may not represent the full 
picture. However, given the quality of the data, I can still look at the basic interaction 
patterns. My first observation was that even with the higher number of initial reads as well as 
raw unique valid pairs, after balancing, there was a  small increase in the looping 
interactions in the non-neuronal population compared to the neuronal population when 
visualized and inspected through the genomewide chromatin interactions heatmaps (Figure 
9.7-1). This should, however, be cautiously interpreted as quantification is required both in 
the biological setup and computational setup.  I then identified the topologically associating 
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domains (TADs) (6.7.1.3 above) from the neuronal and non-neuronal population and 
compared them to the published results (Figure 9.7-1). The number of TADs were also 
marginally higher in the neuronal population (1098) compared to the non-neuronal 
populations (1057). This number, however, might change when the TADs calling is 
performed at a higher resolution (current resolution is 500 kb genomic bins). It may be 
speculated that this may not affect the overall interaction pattern, but may be responsible for 
the differences in the interaction patterns that may be involved in disease mechanism. 
10.2.3 Interaction pattern differences on a single chromosome (chr9) 
and near a single gene (BACE1) 
In the end, I wanted to check the instances of the looping interactions that were different 
between neurons and non-neurons. I looked into the particular chromosome, chr 9 which 
has a very important gene (BACE1) that is involved in the Alzheimer’s disease pathology 
[379, 381, 382, 548, 549]. However, due to the low number of uniquely valid pairs, I 
performed the analysis by the visual inspection of the data which still provided some striking 
evidences in the looping patterns of neurons and non-neurons near the BACE1 gene. The 
data and results should be cautiously interpreted. When I looked at the general interaction 
pattern on chromosome 9, there were few genomic locations with lower number of 
interactions and few genomic locations have a higher number of interactions in neurons 
compared to non-neurons (section 9.7.3 above). For one of the examples, there was a 
reduction in the gene expression pattern (Figure 9.7-5) that has a miRNAs cluster and also 
an increase peak density for H3K27m3 peaks which is a repressive mark. This calls for a 
compressive analysis for the next part of the study in the future. The absence of 500 Kb 
binned resolution TAD in non-neurons may play a role in the looping interaction pattern of 
the BACE1 gene which right now is a speculation. A high resolution TADs map should 
confirm the absence of this particular TAD in the BACE1 gene vicinity. The specific 
interaction profile of the BACE1 gene was crucial to understand and even with the low 
resolution data, I was able to identify that there was a decrease in the interaction pattern of 
the BACE1 genes in non-neurons compared to neurons. Along with that, the enhancer’s 
density was also higher for the neurons near the BACE1 gene compared to the non-neurons 
(Figure 9.7-6). All the results in this pilot study suggest that there is a difference in the 
conformation of the cells from neuronal and non-neuronal population with a distinctive 
interaction pattern but it should be interpreted carefully.  
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11.       Conclusions 
The epigenetic regulation of gene expression plays a major role in memory formation and 
synaptic plasticity. The epigenetic mechanisms involve the regulation of proper gene 
expression by DNA methylation and demethylation, histone modifications and the role of 
noncoding RNAs along with the genetic and environmental factors. Deregulation of these 
epigenetic mechanisms [428, 550-553] along with the disruption of the three dimensional 
architecture of the genome results in a crisscrossing of the complex interconnection of long 
range looping interactions [238, 554] leading to the disease pathogenesis. Understanding 
these mechanisms becomes critical in fast progressing neurodegenerative disorders like 
Alzheimer’s disease, Parkinson’s disease and Amyotrophic Lateral Sclerosis (ALS). The 
need to develop biomarkers for the diagnosis, prognosis, and prediction of the onset of 
Alzheimer’s disease - which can lead to personalized therapeutic tools - is very important. 
The key objectives of my study were to identify putative small noncoding RNAs biomarkers 
by the use of machine learning and statistical methods and get a basic understanding of the 
underlying mechanism that may be probable causes of Alzheimer’s disease by looking into 
the three dimensional topology of the chromatin in the neuronal and non-neuronal samples. 
Those were the two main goals of my study and a brief summary of both aims is presented 
below. 
 
The first aim was to study the epigenetic regulation of information in a neuronal network like 
exosomal transfer of small noncoding RNAs, which leads to the development of putative 
biomarkers for disease diagnosis, prognosis, and prediction. The data suggest that 
exosomes released from neurons mainly reflect the small noncoding RNA composition of the 
parental cells. This data is in line with other studies performed, for example on cancerous 
cells [555-558]. The analysis of CSF exosomes at least in the part that reveals the 
pathological small noncoding RNAome changes occurring in the brain as the top expressed 
miRNAs and piRNAs found in the CSF exosomes are linked to brain function [373, 509, 522, 
559, 560]. This data also suggest that the analysis of miRNAs and piRNAs expression alone 
is suitable for the diagnosis and prognosis of Alzheimer’s disease in an independent 
replication cohort during the biomarker development phase but not sufficiently high for use in 
clinical practice as of now. However, the combination of both the existing clinical protein 
markers like pTAU and Aβ42/Aβ40 ratio and small noncoding RNAs signature (three 
miRNAs, namely hsa-miR-27a-3p, hsa-miR-30a-5p, miR-34c-3p and three piRNAs, namely 
hsa-piR-019949, hsa-piR-020364 and hsa-piR-019324) provides very high accuracy and 
may be used in the clinics for the disease diagnosis and prognosis compared to the use of 
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individual markers. Taking into account that small noncoding RNAs are extremely stable 
[561-563] and are rather unaffected by repeated freezing and thawing cycles our findings 
suggest that both miRNAs and piRNAs [564] should be considered as the additional 
biomarker for diagnosis and patient stratification. It is also reported that the changes in these 
small noncoding RNAs represent a combination of environmental and genetic risk factors 
and not simply Aβ or Tau load providing additional and valuable information for the onset of 
Mild Cognitive Impairment (MCI) and Alzheimer’s disease. Finally, the study reported that 
the analysis of these small noncoding RNAs from CSF exosomes potentially informs about 
many molecular and biological processes that might fail to classify patients when assessed 
individually. This may be the primary reason for the excellent performance of the reported 
piRNAs signature and a good performance for miRNAs signature in predicting the 
conversion of MCI patients from mciStable to mciAD.  
 
Through this study, I also provide various statistical and machine learning toolkits and 
pipelines with open source access to the code. This not only ensures that the results of the 
study can be replicated, but also, at the same time, make sure that the same pipelines can 
be used on a larger cohort so that the data is analyzed in a standard way which will avoid 
various biases that may introduce during data analysis and interpretation of the results. This 
is very important, as before, making any major deduction of the usability of these small 
noncoding RNAs signatures as biomarkers from this study, the data should be systematically 
tested in a study with bigger population size and conducted over a longer period of time in 
the clinical setup. 
 
The second aim was to study the role of dynamic changes in higher order chromatin 
structure that control gene expression programs in neuronal plasticity. This was a pilot study 
with the goal to get a glimpse of the three dimensional organization of the genome inside the 
neuronal and non-neuronal population of the cells and its impact on the genetic and 
epigenetic regulatory network by the use of Chromosome Conformation Capture (3C) based 
technique (3C-seq). The study was successfully performed with the 3C-seq technique in the 
FACS sorted neuronal and non-neuronal nuclei from CA1 (the specific sub region of the 
dorsal hippocampus) in the mouse. The 3C-seq experiment was successful, but due to the 
low input RNA concentration, the library could not be sequenced deep enough to get a 
fragment level resolution data for the analysis. Even with the low resolution data (500 kb 
bins), the study reported that there is a difference in the number of topologically associating 
domains in the neuronal and non-neuronal population of the cells. The study reports many 
regions where there are distinct interaction pattern in the neuronal and non-neuronal cells for 
example between the TSS of a gene and an enhancer mark (H3k4me1); suggesting their 
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involvement in the regulation of a gene that might be a part of the disease pathway. One 
such finding reported a distinct looping interaction pattern of the BACE1 gene with the 
neighboring enhances present in neuronal cells compared to the corresponding non-
neuronal cells. The data and results, however, should be interpreted by carefully as the data 
cannot be binned at a higher resolution for more concrete TAD calling and assessment of 
the looping interactions within those TADs. However, it does provide an overview of how the 
looping interaction pattern is present in the two sub populations of the cells in the CA1 
region. In the future, I want to look at the role of the selected small noncoding RNAs found 
the aim 1 in different neuronal and non-neuronal populations. I also want to see the effects 
of these small noncoding RNAs on the proteome if we knock out some of them to look at the 
gain or loss of function.  
 
In the end, my Ph.D. work will significantly contribute to better understanding on how the 
epigenetic code controls neuronal plasticity and memory function which will help not only to 
better understand the brain, but may also help to identify novel therapeutic avenues to treat 
cognitive dysfunction and complex brain diseases. 
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